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ABSTRACT 
The Role of MeCP2 in Pain and Its Regulation by miRNA 
Melissa Taft Manners 
Seena K. Ajit, Ph.D. 
 
 
 
DNA methylation is a dynamic epigenetic modification and this biological signal is 
read by methyl-CpG-binding protein 2 (MeCP2). MeCP2 regulates gene 
expression through activation, repression and chromatin remodeling and is crucial 
for neuronal development and function. Mutations in MECP2 cause Rett syndrome 
(RTT) and decreased pain perception is reported in children with RTT, suggesting 
MeCP2 function is important in modulating pain. The overall objective of this study 
was to understand the role of MeCP2 in nociception under both physiological and 
pathological conditions. Dorsal root ganglia (DRG) convey noxious stimuli from the 
periphery to the central nervous system. Our previous miRNA profiling of DRG in 
a rodent model for neuropathic pain showed decreased expression of multiple 
miRNAs predicted to target Mecp2. We confirmed MeCP2 upregulation in DRG 
following nerve injury and repression of MeCP2 by miRNAs in vitro. MeCP2 
regulates brain derived neurotrophic factor (BDNF) and downregulation of MeCP2 
by miRNAs decreased Bdnf in vitro. MeCP2 T158A knock-in mice with a mutation 
in the methyl-CpG binding domain of MeCP2, exhibited reduced mechanical 
sensitivity. Mecp2-null and MeCP2 T158A mice have decreased Bdnf in DRG. 
xii 
 
MeCP2-mediated regulation of Bdnf in the DRG could contribute to altered pain 
sensitivity. 
The functional implication of increased MeCP2 is largely unknown. To 
identify regions of the genome bound by MeCP2 in the DRG and the changes 
induced by nerve injury, chromatin immunoprecipitation of MeCP2 followed by 
sequencing (ChIP-seq) was performed. While the number of binding sites across 
the genome remained similar in the spared nerve injury (SNI) model and control, 
SNI induced the redistribution of MeCP2 to transcriptionally relevant regions. To 
determine how differential binding of MeCP2 can affect gene expression, we 
investigated mmu-miR-126, a miRNA locus that had enriched MeCP2 binding in 
the SNI model. Repression of miR-126 and the ensuing downstream molecular 
changes was confirmed using the SNI model, Mecp2-null mice and a neuronal cell 
line. Our study shows a regulatory role for MeCP2 in that changes in global 
redistribution can result in direct and indirect modulation of gene expression in the 
DRG, thereby contributing to epigenetic alterations underlying nerve injury.  
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CHAPTER ONE: Background and Significance 
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INTRODUCTION TO PAIN 
Nociceptive pain is a protective mechanism to guard against potentially damaging 
stimuli. However, chronic pain, characterized by pathological nociceptive 
hypersensitivity [1] is a debilitating condition that affects more than 100 million 
Americans, costing over $600 billion in healthcare related expenses [2]. 
Neuropathic pain is triggered by a lesion or disease of the somatosensory nervous 
system that alters its structure and function [3]. Present treatment options are 
limited to nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, 
and antidepressants, which together provide pain relief to only about 50% of 
patients, clearly highlighting the unmet medical need for such a common and 
widespread ailment [4].  
The Pain Pathway 
Pain processing begins with nociception, a process where noxious stimuli are 
detected by peripheral nociceptors. Cell bodies for these nociceptors are located 
in the dorsal root ganglia (DRG). The DRG has two axonal branches, extending 
both peripherally and centrally to innervate the peripheral target organ and the 
dorsal horn of the spinal cord, ultimately conveying sensory information from the 
periphery to the central nervous system (CNS). The peripheral terminal responds 
to environmental stimuli including heat, cold, and mechanical stimulation. Both the 
peripheral and central terminals contain receptors subject to targeting from 
endogenous molecules. In addition to relaying nociceptive information, both 
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terminals have directed analgesic therapeutics. For example, opioid receptors at 
the central terminal are affected by a spinal delivery of morphine, and topical 
anesthetics block targets at peripheral nociceptors [5]. The DRG are primary sites 
for pain processing and as such have been the focus of much research to identify 
molecular targets of pain neurotransmission. Our goal was to determine changes 
in gene expression and regulation due to peripheral nerve injury, therefore our 
studies have been conducted primarily in the DRG. 
There are two major classes of nociceptors [6]. The first class includes Aδ 
afferent nociceptors, myelinated medium diameter neurons that convey fast pain 
and large diameter Aβ fibers that respond to light touch. The second class of 
nociceptor are the unmyelinated C fibers that convey slow pain and are subdivided 
based on gene expression properties, into peptidergic (expressing substance P, 
calcitonin gene related peptide, tyrosine kinase receptor A) and non peptidergic 
fibers (expressing purinergic receptor P2X3, and Ret receptor for glial cell line-
derived family of neurotrophic factors). These classes of nociceptors innervate 
specific subsections of the dorsal horn of the spinal cord from lamina I to lamina 
V. Projecting neurons within lamiae I and V are the major output from the dorsal 
horn to the brain [7]. These neurons form the ascending pathways, including the 
spinothalamic tract, carrying pain signals to the thalamus which is important for the 
sensory-discriminative aspects of the pain experience, and the 
spinoreticularthalamic tract, carrying pain signals to the brainstem. Additional 
projections to the dorsolateral pons, which communicates with the amygdala is 
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important for processing information relevant to aversive properties of the pain 
experience [5]. 
Animal Models of Pain 
There are several rodent models of neuropathic and inflammatory pain 
generated to investigate the pathophysiology and underlying molecular 
mechanisms. Inflammatory pain models are usually generated by the injection of 
an adjuvant (complete Freund’s adjuvant) or chemical (carrageenan, formalin, 
capsaicin, prostaglandin) into the hindpaw, ankle, or knee joint of rodents [8]. 
Administration of these agents can induce chronic or acute inflammatory pain 
resulting in reduced pain thresholds. 
Peripheral nerve injury models have been developed to better understand 
chronic neuropathic pain. These models involve nerve injuries to the sciatic or 
spinal nerve on one side [9]. Nerve injury models involving the sciatic nerve range 
from a partial or complete transection to ligation or compression. Ligation or 
transection of spinal nerves also induces neuropathic pain [9]. These models 
induce neuropathic pain to varying degrees, depending on the severity of the 
injury. Restriction of injury to one side allows for the stimulation of the injured or 
uninjured paw in the same animal, thereby enabling discrimination of 
hypersensitivity in the ipsilateral injured paw induced by the nerve injury. 
  We employed the spared serve injury (SNI) model of neuropathic pain for 
our studies. This is a partial denervation model, allowing for investigation of both 
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injured primary sensory neurons as well as intact sensory neurons [10]. Figure 1A-
B depicts the nerve injury, where the common peroneal nerve and tibial nerve are 
ligated and sectioned, while the sural nerve remains intact. The model produces 
severe, chronic neuropathic pain, including allodynia, the experience of pain from 
a non-painful stimulation of the skin; and hyperalgesia, an abnormally heightened 
sensitivity to pain. We characterized pain sensitivity by measuring mechanical 
threshold using von Frey filaments (Figure 1C).  
We employed the spared serve injury (SNI) model of neuropathic pain for 
our studies. This is a partial denervation model, allowing for investigation of both 
injured primary sensory neurons as well as intact sensory neurons [10]. Figure 1A-
B depicts the nerve injury, where the common peroneal nerve and tibial nerve are 
ligated and sectioned, while the sural nerve remains intact. The model produces 
severe, chronic neuropathic pain, including allodynia, the experience of pain from 
a non-painful stimulation of the skin; and hyperalgesia, an abnormally heightened 
sensitivity to pain. We characterized pain sensitivity by measuring mechanical 
threshold using von Frey filaments (Figure 1C).  
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INTRODUCTION TO EPIGENETICS 
Epigenetics encompasses heritable alterations in gene expression and chromatin 
without accompanying changes in the DNA sequence. Epigenetic mechanisms are 
dynamic and respond to changes in the environment and cellular experiences, 
resulting in cellular differences in function and provide a mechanism to document 
history [11]. Epigenetic modifications cause remodeling of chromatin resulting in 
regulation of gene expression. There are three major mechanisms of epigenetic 
regulation, including DNA methylation, noncoding RNAs and histone 
modifications. In this thesis, we focus on miRNA-mediated regulation of gene 
expression and DNA methylation, specifically methyl-CpG-binding protein 2 
(MeCP2), a protein that binds to methylated DNA. 
microRNAs 
MicroRNAs (miRNAs) are endogenous ~22nt RNAs that regulate gene expression 
usually by binding to the 3’ untranslated region (UTR) of targeting mRNAs for 
cleavage or translational repression. miRNAs are encoded in various regions of 
the genome, including introns and exons of both coding and non-coding genes. 
Promoter regions have not been mapped for most miRNAs. They often have 
multiple transcriptional start sites [12], and promoters can be distinct or shared with 
the promoter of the host gene [13]. Following transcription, the primary miRNA 
undergoes several steps of maturation and processing, nuclear export, and finally 
the mature miRNA is packaged into RNA-induced silencing complex formation 
7 
 
[14]. miRNAs repress gene expression through two mechanisms; repressing 
translation and mRNA degradation. mRNA degradation is catalyzed by 
deadenylating enzymes. Deadenylated mRNAs are decapped and then degraded 
by exoribonuclease 1. Approximately 60-90% of miRNA-mediated repression 
occurs through this mechanism in cultured mammalian cells [15]. Partial 
complementarity of the seed sequence is a determinant in target recognition and 
is sufficient to trigger translational silencing [16]. In some cases, translation is 
initiated but miRNA mediated disruption in translation results in a small peptide 
that is quickly degraded [17].   
DNA Methylation 
DNA methylation is a chemical addition of a methyl group onto the 5th carbon of 
cytosine which can directly regulate gene expression. The majority of DNA 
methylation occurs at CpG sites, referring to cytosine and guanine linked with a 
phosphodiester bond. Regions of DNA with a particularly high occurrence of CpG 
sites are called CpG islands [18]. They are defined as regions of more than 200 
bases with a CpG content of 50% or greater. About 60% of gene promoters contain 
CpG sites, and they are usually unmethylated [19]. Methylation at CpG islands is 
generally associated with gene silencing, and unmethylated CpG islands are 
associated with gene expression [20]. DNA methylation can directly inhibit 
transcription by impairing transcription factor binding [21]. CpG sites also occur 
outside of CpG islands. Recently, it has been shown that DNA methylation can 
occur outside of the traditional CpG site [22]. In mouse dentate neurons, 75% of 
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methylation occurred at CpG sites, while 25% of methylation occurred at CpH 
sites, where H can be adenine, cytosine or thymine.  
The broad classification of enzymes involved in DNA methylation are; 
“writers” to establish methylation patterns, “erasers” to remove methyl groups from 
nucleotides, and “readers” that recognize, and bind to methylation patterns. DNA 
methyl transferases (Dnmts) function as “writers” by transferring the methyl group 
of cosubstrate, S-adenyl methionine, to the fifth carbon of cytosine [21].  Dnmt1 
maintains methylation in mitotic cells by recognizing hemimethylated sites and 
replicating the methylation pattern in the daughter cells. Dnmt3a and Dnmt3b are 
responsible for de novo methylation, modifying the genome in new ways. The role 
of “eraser” enzymes is to demethylate DNA. Demethylation occurs through a series 
of enzymatic reactions creating intermediate products of 5-methyl cytosine. The 
most studied intermediate is 5-hydroxymethylcytosine (5-hmc), which is enriched 
in active genes in the CNS [23]. This reaction is catalyzed by ten-eleven 
translocation enzyme and can further oxidize 5-hmc, producing 5-formylcytosine 
and 5-carboxylcytosine [24]. The base excision repair process removes the 
oxidized cytosine and replaces it with a non-methylated cytosine [21, 25]. Proteins 
containing a methyl-CpG binding domain (MBD) “read” DNA methylation patterns. 
Proteins in this family include MBD1-MBD4 and methyl-CpG-binding protein 2 
(MeCP2). These proteins can decipher methylation patterns before binding to 
methylated DNA, and recently, reader proteins have been found to bind to modified 
cytosine cites [23, 26].  
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MeCP2 is a reader protein that has been implicated in pain, and is the focus 
of this study. We investigated how MeCP2 is regulated by miRNAs and identified 
regions of the genome that are differentially bound by MeCP2 after peripheral 
nerve injury. 
MeCP2 
MeCP2 was the first protein identified containing an MBD. Several additional DNA 
and protein interacting domains have been characterized (Figure 2). The MBD is 
the primary region of interaction between MeCP2 protein and DNA, and it enables 
MeCP2 to specifically bind to methylated CpG sites [27]. Chromatin 
immunoprecipitation studies have supported this finding by showing preferential 
MeCP2 binding to methylated regions in the brain, and mutations in this region 
reduce the affinity of MeCP2 for methylated DNA [28]. This study also quantified 
the abundance of MeCP2 in the nuclei with levels as high as the histone octamer. 
This genome-wide binding pattern is interpreted to play a role in dampening 
transcriptional noise as opposed to regulating expression of individual genes. DNA 
methylation can occur outside CpG sites, and MeCP2 was shown to bind to these 
unconventional methylated regions in the brain and in cultured neurons [22]. In 
cerebellar cells, the MBD also has an affinity, albeit weaker, for 5-hmc and MeCP2 
was shown to be a major binding protein for 5-hmc in active genes [23]. This study 
demonstrated that the R133C mutation occurring in RTT patients within the MBD 
of MeCP2 inhibits binding to 5-hmc, suggesting that the interaction of MeCP2 with 
this modified cytosine is important in symptoms associated with RTT. 
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 MeCP2 can also bind to DNA at regions other than the MBD site. Recently, 
MeCP2 was characterized to contain three AT-hook DNA-binding motif domains 
[29]. High-mobility group AT-hook family proteins (HMGA) often contain 2-3 AT-
hook domains, with a flexible polypeptide linker. This allows multiple contact 
locations to alter chromatin conformation. Mutations occurring within the AT-hook 
domain of the C-terminus of MeCP2 disrupt MeCP2 DNA binding, and could further 
contribute to RTT pathology [29] . 
MeCP2 was first identified as a methylation dependent transcriptional 
repressor. MeCP2 contains a transcriptional repression domain (TRD), and was 
shown to repress genes with methylated promoters, but not unmethylated 
promoters [30]. Transcriptional profiling of the hypothalamus from Mecp2-null mice 
showed 15% of affected genes were downregulated in the absence of MeCP2 [31]. 
Further studies also show that MeCP2 can interact with histone deacetylate 
(HDAC) complex containing SIN3A, and nuclear receptor co-repressor (NCOR) 
and silencing mediator of retinoic acid (SMRT), the binding domain of which 
resides in the TRD of MeCP2 [32]. The significance of MeCP2 interaction with 
HDAC is further supported pharmacologically, as transcriptional repression is 
attenuated with an HDAC inhibitor [33]. MeCP2 represses a large number of genes 
in cultured neurons by preferentially binding to long genes containing methylated 
CpA sites [34]. Transcriptional profiling of the brain from Mecp2-null mice was one 
of the first studies to demonstrate the activator role of MeCP2 [31]. In these mice, 
85% of the genes affected were downregulated in the absence of MeCP2, 
11 
 
suggesting that MeCP2 has a role in activation of these potential targets. 
Chromatin immunoprecipitation (ChIP) studies confirmed MeCP2 binding to a 
subset of genes, and immunoprecipitation studies and proteomic analysis revealed 
that MeCP2 binds to the promoter of activated genes in a complex with the 
transcription factor, cyclic AMP-responsive element-binding protein 1 (CREB1) 
[31].  
Collectively, these studies demonstrate that MeCP2 binds to methylated 
DNA in a genome-wide manner, thus affecting a large number of downstream 
genes. MeCP2 additionally recruits cofactors and can modify chromatin to globally 
reduce transcriptional noise as well as influence transcription of specific target 
genes. 
  
12 
 
EPIGENETIC REGULATION AND PAIN 
Molecular and genetic studies have shown a fundamental role for 
epigenetics in key biological processes and how epigenetic aberrations result in 
disease. Epigenetic regulation has been explored in the context of peripheral 
inflammation, plasticity, and cortical pain processing [35]. Nerve injury can induce 
alterations in chromatin structure and influence molecular and cellular function, 
which ultimately have the potential to lead to symptoms ranging from allodynia, 
hyperalgesia, anxiety, and depression [36]. Here we explore alterations in miRNAs 
and DNA methylation that occur in response to peripheral nerve injury.  
miRNAs and Pain 
Maintaining appropriate levels of miRNA is very important, as aberrant expression 
of miRNAs are reported in various diseases, including pathological pain. The role 
of miRNAs in peripheral pain pathways was globally evaluated using a conditional 
deletion of Dicer, an enzyme involved in the biogenesis of miRNA, in nociceptors 
important for inflammatory pain [37]. Deletion of Dicer lead to a broad increase in 
mRNAs in the DRG. Though these mice had normal acute pain thresholds, 
inflammatory pain was attenuated, as inflammatory mediators could not enhance 
the excitability of sensory neurons. Therefore, disruption of miRNA processing in 
the DRG was sufficient to reduce inflammatory pain [37]. 
13 
 
miRNA profiling studies 
Surveying tissue and fluids for miRNAs in a disease or animal model can 
identify how a pathology affects miRNA levels. miRNA profiling conducted in the 
blood of several animal models of neuropathic, inflammatory, and chemotherapy 
induced pain resulted in uniquely dysregulated miRNA profiles in each model [38]. 
Interestingly, all models included dysregulated miRNAs predicted to target factors 
involved in the Wnt signaling pathway. Studies in DRG sensory neurons following 
chemotherapy induced pain identified 57 dysregulated miRNAs [39]. Of these 
differentially expressed miRNAs, inhibition of miR-1a in the DRG alleviated the 
pain phenotype associated with this model through increased expression of the 
Clcn3 chloride channel. We previously determined miRNA alterations in the DRG 
after peripheral nerve injury, and found differential expression of 63 miRNAs [40]. 
Table 1 shows a subset of miRNAs downregulated after nerve injury predicted to 
target MeCP2. Computational target prediction algorithms are commonly used to 
identify candidate genes targeted by miRNAs. Algorithms are diverse and use 
different parameters to provide candidate target genes [41]. However, these 
computational programs use different algorithms and predict different lists of 
putative targets for a given miRNA [42], yielding both false-positive and false-
negative predictions. Nevertheless, prediction tools are immensely valuable in 
identifying potential targets that can be experimentally validated. 
 miRNA profiling has also been conducted in various fluids from patients with 
painful diseases. Patients suffering with fibromyalgia have a low pain threshold. 
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Compared to healthy controls, 9 miRNAs were downregulated in the cerebral 
spinal fluid from these patients [43]. Of these miRNAs, miR-145-5p positively 
correlated with levels of pain and fatigue. Patients with irritable bowel syndrome 
have higher circulating levels of miR-1250 and miR-342 than healthy controls [44]. 
These miRNAs are associated with inflammatory pathways and pain signaling. 
They could serve as biomarkers and additionally, could contribute to the abdominal 
pain associated with IBS.  Patients with complex regional pain syndrome (CRPS) 
have a unique miRNA signature compared to control subjects, with 18 differentially 
expressed miRNAs [45]. These miRNA profiles can be useful for both patient 
stratification and future therapeutic intervention.  Ketamine is beneficial in treating 
CRPS patients, and 33 miRNAs were differentially expressed in responders 
compared to poor responders in the pre-treatment blood samples [46].  
Together, these data demonstrate that pathological pain can affect miRNA 
expression in tissue and in circulation. With the wide range of downstream targets 
for each miRNA, large scale effects could ensue from dysregulated miRNAs. 
Additionally, dysregulated miRNAs have utility as biomarkers, and individual or 
groups of miRNAs could be considered for therapeutic intervention. In our study, 
we demonstrate how miRNAs downregulated in the DRG after nerve injury lead to 
upregulation of target expression and downstream molecular mechanisms.  
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miRNAs attenuate pain behavior 
In addition to pain affecting miRNA expression, miRNAs have been shown to 
therapeutically attenuate hypersensitivity in animal models of pain.  An 
inflammatory stimulus caused methylation of the miR-219 promoter and reduced 
miR-126 levels in spinal neurons [47]. This resulted in increased expression of its 
target, CaMKIIγ. Injection of miR-219 reversed thermal hyperalgesia and 
mechanical allodynia induced by the inflammatory model. miR-103 was shown to 
regulate three subunits of Cav1.2-comprising L-type calcium channel in the dorsal 
horn [48]. Knockdown of miR-103 in rodents resulted in hypersensitivity to pain, 
while overexpression decreased pain threshold after peripheral nerve injury. miR-
146a-5p was shown to be downregulated in a spinal nerve ligation model [49]. 
Intrathecal injection of miR-146a-5p attenuated mechanical allodynia and 
decreased expression of TNF receptor associated factor, involved in 
neuroinflammation. miR-124 is expressed in microglia in the CNS. Intrathecal 
administration of miR-124 reversed hyperalgesia induced by carrageenan in an 
inflammatory pain model, and also prevented the development of mechanical 
allodynia in the SNI model [50]. This study interestingly shows how a single miRNA 
can both reduce sensitivity induced by inflammatory and neuropathic pain models. 
Another study of miR-124 showed reduced paw licking, a nociceptive behavior 
associated with a formalin model of chemical-induced pain, and inhibition of miR-
124 further increased nociceptive behavior [51]. These effects were proposed to 
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be mediated through regulation of MeCP2 and expression of its downstream 
target, brain derived neurotrophic factor (Bdnf). 
These examples demonstrate that miRNA expression is affected by disease 
and this could have consequences on downstream molecular targets leading to 
progression or worsening of the disease. The studies mentioned above indicate 
that administration of miRNAs can attenuate hypersensitivity associated with a 
pain state and could therefore be considered for therapeutic intervention. In this 
study, we explore miRNA-mediated regulation by confirming binding and 
repression of bioinformatically predicted targets. We also employ in vivo and in 
vitro overexpression and inhibition studies to validate target expression and 
investigate consequences on pain behavior. 
DNA Methylation and Pain 
DNA methylation patterns are important, as aberrant methylation can result in 
several pathologies involving learning, memory, and neuronal development and 
function [52, 53]. Studies have also shown alterations in DNA methylation in rodent 
models of neuropathic pain. A genome-wide methylation study conducted in the 
DRG 24 hours after peripheral nerve injury reported global remodeling of DNA 
methylation [54]. Differentially methylated CpG sites were found in promoters, 
exons, and introns occurring at thousands of CpG sites independent of CpG 
islands. Affected genes were associated with neurobiologically relevant 
mechanisms in the peripheral nervous system and nerve injury. Differentially 
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methylated CpG sites within genic regions showed hypermethylation of 82% and 
hypomethylation of 18% of affected genes. Genes with hypermethylated 
promoters were shown to be both upregulated and downregulated. A recent study 
investigating methylation changes induced by chronic pain 9 months after SNI 
surgery observed over 12,000 methylated gene promoters in the prefrontal cortex. 
Increased methylation was also observed in circulating T-cells [55]. In the lumbar 
spinal cord, a chronic constriction injury model of neuropathic pain caused an 
increase in global DNA methylation levels 14 days after surgery, and an 
upregulation of MeCP2 [56]. This increase in methylation and MeCP2 expression 
was partially prevented with intrathecal administration of a DNA methyltransferase 
inhibitor, 5-azacytidine (5-AZA). A global methylation study conducted in the brain 
6 months after SNI surgery found decreased global  methylation in the amygdala 
and prefrontal cortex [57]. Interestingly, environmental enrichment reversed the 
abnormal global methylation in the prefontal cortex in SNI model mice. Nociceptive 
thresholds were positively correlated with global methylation. 
Therapeutic potential DNA methylation 
An important aspect of epigenetics, is the dynamic nature of these mechanisms, 
and therefore they are inducible as well as reversible. Epigenetic reprogramming 
has recently been demonstrated, by converting differentiated cells into pluripotent 
states [58]. Since epigenetic marks are labile, reprogramming using 
pharmacological modulators could provide an avenue for therapeutic intervention 
[59]. This has been demonstrated with DNMT inhibitors, 5-azacytidine and 
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decitabine, currently approved for clinical use in cancer [60, 61], and is being 
extended to other therapeutic areas.  It was shown that the chronic constriction 
injury (CCI) model induced a global increase in DNA methylation levels in the 
spinal cord [56]. Administration of 5-azacytidine not only reduced methylation 
levels, but alleviated both the mechanical allodynia and thermal hyperalgesia 
associated with this model. Another study demonstrated that an intraperitoneal 
injection of DNMT inhibitor, 5-azacytidine-2’-deoxycytidine reduced incision-
induced nociceptive behavior [62]. Mechanical allodynia, thermal hyperalgesia, 
and paw swelling associated with hindpaw incision were alleviated, suggesting 
both an analgesic and anti-inflammatory effect. Therapeutics targeting epigenetic 
mechanisms thus holds a promising future. However, these mechanisms are 
global and therefore lack of drug selectivity and side effects can potentially have 
large repercussions.  
 MeCP2 and Pain 
Abnormal sensory thresholds observed in RTT patients initially linked MeCP2 to 
pain [63]. Studies investigating acute pain threshold of mice mimicking MeCP2 
mutations observed in patients show reduced pain sensitivity [64-67]. Additionally, 
expression levels of MeCP2 are affected in nerve injury models and inflammatory 
pain models. Together, the RTT patients and animal models implicate that 
regulated levels of MeCP2 are important for normal pain thresholds.  
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Rett Syndrome and pain 
Mutations in MECP2, an X-linked gene, can cause RTT, an autism spectrum 
disorder leading to severe physical and neurological disabilities. Onset of 
symptoms occur after 6 to 18 months of age and include developmental 
regression, loss of hand skills with gain of stereotypical hand movements, impaired 
mobility, loss of speech, and respiratory disorders [68]. In addition, decreased pain 
perception is often reported by the caretakers of children with RTT. Clinical case 
studies include generally impaired nociception [69], and a patient after corrective 
surgery for scoliosis required very little postoperative analgesic compared to 
healthy children who had the same surgery [70]. A study evaluating the response 
of parents to questionnaires from the Australian Rett Syndrome Database and the 
International Rett Syndrome Phenotype database, assessed the prevalence of 
aberrant pain sensitivity of RTT patients [63]. In the total population study, the 
prevalence of an abnormal pain response was over 75%, with 86% of those 
patients having a decreased response to painful stimulus. Patients were also 
stratified based on 12 different genomic mutations in MECP2, and in each 
subgroup the majority of patients presented with decreased pain sensitivity. 
MeCP2 expression in pain 
MeCP2 expression is influenced by pain. In a time course evaluation of 
MeCP2 expression after SNI surgery, MeCP2 was found to be downregulated 10 
days post-surgery in the DRG, and upregulated in the dorsal horn after 7 days. 
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These effects seem to be temporal, as we evaluated expression of MeCP2 in the 
DRG and dorsal horn 4 weeks post SNI surgery and found upregulation in the DRG 
[64] and downregulation in the dorsal horn (Figure 3), which was also observed by 
others [71]. MeCP2 is expressed in nociceptive and non-nociceptive neurons in 
the DRG [67], and neurons, oligodendrocytes and astrocytes in the dorsal horn 
[71]. After SNI surgery, MeCP2 expression is decreased in damaged neurons of 
the dorsal horn [71]. MeCP2 expression levels were also modulated by 
inflammatory pain as expression was increased in the dorsal horn 7 days after 
inflammatory stimulus [71]. Inflammatory stimulus increased phosphorylation of 
MeCP2 in lamina I projection neurons in the dorsal horn, which are essential for 
the development of pain [72]. This resulted in the dissociation of MeCP2 from the 
genome, thereby alleviating repression of genes linked to pain in projection 
neurons. The dynamic expression of MeCP2 in the dorsal horn and the DRG after 
nerve injury suggests that nerve injury and inflammation induces expressional 
changes in MeCP2. 
Central mechanisms of pain and morphine seeking behavior are also linked 
to MeCP2. MeCP2 directly represses the transcriptional repressor, histone 
dimethyltransferase G9a, resulting in increased Bdnf [73]. This mechanism 
contributes to the regulation of the emotional response to pain and opioid reward. 
MeCP2 mediated repression of the glutamate AMPA receptor subunit, Glua1, 
contributes to the morphine-seeking behavior associated with morphine 
withdrawal administered after pain [74]. Importantly, these studies demonstrate 
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that nerve injury and self-administration models can result in the dynamic binding 
of MeCP2 to genes and promoters thereby directly and indirectly affecting gene 
expression. 
Thus, the expression levels of MeCP2 as well as the dynamic binding of 
MeCP2 to the genome contribute to pain sensitivity. Further studies are needed to 
understand how expression changes in the DRG lead to alterations in gene 
expression and the progression of pain pathology. 
Mouse models of RTT 
Over 600 unique mutations resulting in RTT occur in the gene encoding MECP2, 
with 9 mutations accounting for over 75% of cases [75]. There are several animal 
models created to recapitulate the human condition, ranging from point mutations 
to complete Mecp2 knock out. Mice harboring these genetic mutations closely 
mimic symptoms found in humans.  
The pain thresholds of several Mecp2 mutant mouse lines have been 
evaluated. A mouse line generated by disrupting the 3’UTR of MeCP2 resulted in 
a 50% reduction in transcript and protein levels of MeCP2 [65]. This mutation 
resulted in phenotypic abnormalities consistent with RTT. In addition to the many 
behavioral alterations associated with RTT, they observed increased threshold in 
the hot plate test, indicating reduced thermal sensitivity compared to wild type 
littermates. Another study conducted by the same group assessed female    
Mecp2-/+ mice in two different background strains [66]. The thermal sensory 
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thresholds of these mice were significantly increased in the hot plate test, again 
indicating decreased pain sensitivity. Overexpression of MeCP2 [76] increased 
mechanical and thermal pain threshold [67]. These studies show that the reduced 
pain sensitivity observed in RTT patients is reproduced in mouse models. Both 
increased and decreased MeCP2 levels contribute to reduced pain sensitivity. 
Collectively, these data suggests an important role for MeCP2 in nociception, and 
disruption of MeCP2 expression could alter pain phenotype. 
In our study we used mouse models of RTT for molecular characterization 
and for assessment of pain behavior. The Mecp2-null mouse line was generated 
by deleting all but the amino-terminal 8 amino acids of MeCP2 [77]. MeCP2 is an 
X-linked gene, therefore females are heterozygote Mecp2-/+ mice and males are 
hemizygote Mecp2-/y mice, with no detectable levels of MeCP2 transcripts or 
protein. Mice also develop a severe RTT phenotype with a delayed onset of 
symptoms. Thus, these mice serve as an excellent model to study molecular 
alterations that occur in the absence of MeCP2 in the DRG. Female mice are very 
important for studying the phenotype associated with RTT. However, we used 
male mice, as our goal was to assess the role of MeCP2 in pain and male 
hemizygotes are complete MeCP2 knock outs. Male mice die at a young age and 
have symptoms that make evaluation of sensitivity unreliable, therefore, we did not 
conduct a behavioral assessment of these mice.  
For both molecular and behavioral characterization, we used the MeCP2 
T158A knock in mouse [78], which recapitulates one of the most common 
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mutations associated with RTT. The point mutation in threonine 158 results in the 
conversion to either methionine or alanine and disrupts the MBD. Over 70% of 
patients with this mutation have decreased pain sensitivity [63]. These mice 
develop RTT like phenotypes, similar to those observed in Mecp2-null mice, 
including age-dependent developmental regression, motor dysfunction, and 
learning and memory deficits. This mutation leads to decreased MeCP2 
expression, and increased expression of targets normally repressed by MeCP2. 
ChIP results indicated reduced binding to methylated loci, and reduced affinity for 
methylated DNA. Therefore, the MeCP2 T158A mouse serves as an excellent 
model to assess how a disruption in the methyl binding domain of MeCP2 affects 
pain sensitivity, and ensuing molecular effects in the DRG. We used male 
Mecp2T158A/y hemizygotes for our studies. 
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REGULATION OF MECP2 BY MIRNAS 
Regulation of MeCP2 is of great interest as aberrant expression of MeCP2 leads 
to neurological disorders. MeCP2 is subjected to regulation by miRNAs through 
confirmed and predicted binding sites within the 8kb 3’ UTR. Further exploring the 
transcriptional degradation and translational repression of MeCP2 by miRNAs in 
the context of pain is a focus of our study. 
 Several miRNAs have been confirmed to regulate MeCP2 through 
transcriptional degradation or translational repression. miR-132 overexpression in 
cultured cortical neurons decreased MeCP2 expression levels, and also lead to 
reduced expression of the MeCP2 target, Bdnf [79]. Both Bdnf and miR-132 levels 
are decreased in Mecp2-null mice compared to wild type littermates, indicating that 
MeCP2 activates expression of miR-132. Additionally, inducing phosphorylation of 
cAMP response element-binding protein (CREB) increased miR-132 levels and 
decreased MeCP2 expression. Together, in vivo and in vitro studies demonstrate 
the homeostatic regulation of MeCP2 by miR-132.  
MeCP2 represses expression of miR-212 in the dorsal striatum, and this 
regulation leads to reduced cocaine self-administration in rats [80]. Conversely, 
overexpression of miR-212 repressed MeCP2 expression, and the inhibition of 
endogenous miR-212 increased MeCP2 in vitro. Overexpression of miR-212 in the 
dorsal striatum reduced MeCP2 levels and cocaine intake in a cocaine self-
administration model conducted in rats. This relationship indicates a negative 
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feedback state, where MeCP2 inhibits miR-212, and the opposite relationship is 
also true in the dorsal striatum.  
Patients with Beckwith-Wiedemann syndrome, a disease characterized by 
overgrowth present at birth and increased risk of cancer, have imprinting defects 
that lead to over expression of miR-483-5p. Fibroblasts from these patients contain 
high levels of miR-483-5p and decreased levels of MeCP2 [81]. MeCP2 
overexpressing cells have an abnormal dendritic spine phenotype and miR-483-
5p mediated repression of MeCP2 in these cells rescued the phenotype. 
Formalin injection into the hindpaw induces inflammatory pain, and this 
results in downregulation of miR-124a in the spinal cord [51]. miR-124a was shown 
to reduce expression levels of MeCP2, and its target Bdnf. Injection of miR-124a 
reduced the pain phenotype associated with this model, while inhibitors of 
endogenous miR-124a increased  pain behavior.  
These studies demonstrate the importance of precise control of MeCP2 and 
regulatory miRNAs and their potential therapeutic role. Although the regulatory role 
of the above miRNAs has been confirmed, there are many other miRNAs predicted 
to target MeCP2. Our study investigates miRNA-mediated regulation of MeCP2 
focusing on a subset of miRNAs that are dysregulated in pain. 
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OBJECTIVES AND RESEARCH OVERVIEW 
Mutations in MECP2 cause RTT, and decreased pain sensitivity is commonly 
observed in RTT patients, suggesting normal MeCP2 function is important in 
modulating pain [63]. An earlier study in our laboratory identified 63 miRNAs that 
were differentially expressed in the DRG from a rodent model of neuropathic pain 
[40], including 12 downregulated miRNAs bioinformatically predicted to interact 
with the MeCP2 3’UTR, listed in Table 1 [41]. Modulation of MeCP2 has been 
observed in the DRG and spinal cord from rodent models of pain [71, 82]. Our 
studies of DRG from the SNI model of neuropathic pain showed an increase in 
MeCP2 expression. The combination of downregulation of miRNAs predicted to 
target MeCP2 and increased MeCP2 expression in DRG suggests that modulation 
of MeCP2 could be miRNA-mediated. We hypothesize that the downregulation of 
miRNAs induced by SNI contributes to increased MeCP2 expression in the DRG. 
This increase in MeCP2 and alterations in its binding can lead to dysregulation of 
gene expression (Figure 4). These concepts are explored through two specific 
aims, as described below. 
Aim 1: Determine whether miRNAs downregulated in neuropathic pain can 
directly modulate MeCP2 expression. To determine if a subset of miRNAs 
downregulated in neuropathic pain can regulate MeCP2 expression, we used 
reporter assays and confirmed binding of miR-132, miR-301 and miR-19a to the 
MeCP2 3’UTR. Overexpression of these miRNAs in Neuro 2a cells decreased 
MeCP2 expression, while inhibitors increased expression. Furthermore, MeCP2 is 
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a transcriptional regulator of BDNF, and miRNA mediated repression of MeCP2 
resulted in its downregulation. BDNF is upregulated in DRG neurons from 
neuropathic pain models [83, 84]. We found that MeCP2 T158A mice have 
reduced pain sensitivity, similar to the RTT phenotype, and also have reduced Bdnf 
transcripts in the DRG. Confirmation of MeCP2 regulation of Bdnf in the DRG and 
disruption of this system in pain provide a mechanistic link for MeCP2 expression 
in mediating pain. 
Aim 2: Determine differential binding of MeCP2 to the genome in an SNI 
model and investigate resulting changes in gene expression. To determine 
genes that were differentially bound by MeCP2 in the SNI model, we conducted 
chromatin immunoprecipitation sequencing (ChIP-seq). Comparative analysis of 
ChIP-seq results from SNI and sham controls identified a redistribution of MeCP2 
to transcriptionally relevant regions and non-coding RNAs. Further analysis 
revealed an enrichment of MeCP2 binding to the miR-126 locus, resulting in 
repression of miR-126. We investigated the expression levels of miR-126 and its 
targets in the DRG from SNI model mice as well as Mecp2-null mice to determine 
expression changes in the absence of MeCP2. We further explored the effect of 
miR-126 overexpression in vitro and in vivo by measuring target expression and 
effects on pain behavior in the SNI model.  
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CHAPTER 1: Figure legends and Figures 
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Figure 1: SNI model of neuropathic pain  
The SNI model was used in this study to induce neuropathic pain from peripheral 
nerve injury A, Partial deneravation of the sciatic nerve, including the common 
peroneal and tibial nerve, while the sural nerve remains intact. B, Nociception can 
be measured using the lateral portion of the hind paw, which is innervated by the 
sural nerve. C, von Frey filaments were used to measure the mechanical threshold 
of mice after SNI or sham surgery. Figure adapted from I. Decosterd, C.J. Woolf. 
Pain 87 (2000) 149-158. 
 
 
  
30 
 
Figure 1 
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Figure 2: Domains of MeCP2 
MeCP2 has several DNA binding domains and protein binding domains. MBD: 
Methyl CpG binding domain, TRD: Transcriptional repression domain, NID: 
NCOR-SMRT interaction domain (NCOR= nuclear receptor co-repressor, SMRT 
=silencing mediator of retinoic acid), H1-H3: AT hook domains 
 
33 
 
 Figure 2  
34 
 
 
Figure 3: Expression of MeCP2 in the dorsal horn after SNI surgery  
It was previously reported that MeCP2 expression is decreased in the dorsal horn 
following SNI surgery. We measured expression levels 4 weeks after surgery. A, 
Mecp2 mRNA levels were not significantly decreased the SNI model after 
peripheral nerve injury. B, MeCP2 protein was significantly decreased after SNI 
surgery. Significance determined using Student’s t-test p value *** < 0.001. 
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Figure 4: Schematic of our hypothesis; molecular changes occurring in the DRG 
after nerve injury 
After peripheral nerve injury, miRNAs that are predicted to repress MeCP2 
expression are downregulated, while MeCP2 protein is upregulated. MeCP2 can 
both activate and repress gene expression, and we predict that increased 
expression could lead to changes in gene regulation. Therefore, we hypothesize 
that increased MeCP2 expression can both induce upregulation and 
downregulation of genes linked to pain.  
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Figure 4 
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Table 1: Significantly downregulated miRNAs following SNL surgery predicted to 
target the 3’UTR of MeCP2 
miRNA profiling was conducted on rodent DRG after peripheral nerve injury. Of 
the 63 miRNAs altered, 12 miRNAs predicted to target MeCP2 were decreased in 
the L4 and L5 ipsilateral DRG compared with the contralateral DRG. These 
miRNAs were derived based on the filters of the t-test p value <0.01. The table 
was sorted by fold change for the SNL L4. Minus sign indicates downregulation. 
miRNAs selected for experimental validation are highlighted in yellow.  
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CHAPTER TWO: miRNA Mediated Regulation of MeCP2 in the 
DRG after Nerve Injury 
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ABSTRACT 
Nerve injury induces chronic pain and dysregulation of microRNAs in the dorsal 
root ganglia (DRG). Several downregulated microRNAs are predicted to target 
methyl-CpG-binding protein 2 (MeCP2) transcript. MECP2 mutations cause Rett 
syndrome (RTT) and these patients report decreased pain perception. We 
confirmed MeCP2 upregulation in DRG following nerve injury and repression of 
MeCP2 by miRNAs in vitro. MeCP2 regulates brain derived neurotrophic factor 
(BDNF) and downregulation of MeCP2 by microRNAs decreased Bdnf in vitro. 
MeCP2 T158A mice exhibited reduced mechanical sensitivity and Mecp2-null and 
MeCP2 T158A mice have decreased Bdnf in DRG. MeCP2-mediated regulation of 
Bdnf in the DRG could contribute to altered pain sensitivity. 
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INTRODUCTION 
Chronic pain is a prevalent, disabling health condition affecting more than 100 
million people in the United States [85]. Neuropathic pain caused by injury or 
dysfunction of the nervous system can result in peripheral and central 
sensitization, a state of hyperexcitability due to reduction in threshold and an 
amplification in the responsiveness of nociceptors [86]. Elucidation of signaling 
pathways underlying pain hypersensitivity is crucial in improving our understanding 
of molecular mechanisms that drive plasticity in the nervous system promoting the 
development and maintenance of chronic pain states [5]. Animal models of 
neuropathic pain have been pivotal in the exploration of molecular mechanisms of 
pain underlying nerve injury [87]. Our miRNA profiling study in the DRG from a 
nerve injury model identified 63 miRNAs differentially regulated compared to sham 
controls [40]. Bioinformatic prediction indicates 12 downregulated miRNAs are 
predicted to target the 3’ untranslated region (UTR) of Mecp2. Translational 
repression of MeCP2 mediated by binding of miRNAs to the 3’UTR has been 
reported [51, 79, 81, 88, 89].  
MeCP2 binds methylated DNA, and together with co-repressors or 
transcriptional activators, mediates downstream changes in gene expression 
either directly or by altering chromatin structure [31, 90].  Mutations in the X-linked 
MECP2 gene cause RTT [91, 92]. Decreased pain perception is commonly 
reported in children with RTT [63, 93]. The abnormal sensitivity can be as high as 
75%, with a potential relationship between hyposensitivity and specific mutations 
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in the MECP2 gene [63]. The observations from RTT patients indicate that 
decreased functional MeCP2 contributes either directly or indirectly to reduced 
pain sensitivity. Since reduced pain sensitivity observed in RTT patients results 
from a decrease in functional MeCP2 protein, we postulated that a decrease in 
miRNAs that bind and repress translation of MeCP2 will cause an increase in 
MeCP2 levels and thus contribute to hypersensitivity. 
MeCP2 can mediate downstream transcriptional changes of a large number 
of genes and depending on its interacting protein partners and target genes, 
MeCP2 can act either as an activator or repressor [31, 94]. MeCP2 is a known 
regulator of Bdnf  [95], a neurotrophin important in both neuronal development and 
peripheral pain mechanisms [96]. BDNF levels in the hypothalamus correlated with 
MeCP2 levels, with lower levels in Mecp2-null mice and higher levels in MECP2 
overexpressing mice compared to controls [31]. The role of BDNF in both 
inflammatory and neuropathic pain is well established [84, 97-99]. Here we 
investigated if miRNAs downregulated in a rodent model of neuropathic pain that 
modulate MeCP2 expression can induce changes in Bdnf levels in Neuro 2a cells. 
Several mouse models have been generated for investigating MeCP2 
function [100], including alteration of the endogenous Mecp2 gene, or introduction 
of the human MECP2 gene with RTT-associated mutations. One of the most 
common mutations observed in RTT is in amino acid T158, located at the C 
terminus of the methyl-CpG binding domain of MeCP2. It has been reported that 
70.6% of patients with this mutation have decreased pain sensitivity [63]. The 
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phenotype of MeCP2 T158A knockin (KI) mice resembles developmental 
symptoms found in RTT patients [78]. MeCP2 T158A mice showed a reduction in 
MeCP2 binding to methylated DNA and a decrease in MeCP2 protein stability. 
Female Mecp2+/- mice with a conditional mouse allele that expresses 50% of the 
wild-type level of MeCP2 had a slower reaction to a conductive heat stimulus [65, 
66]. We sought to assess the pain sensitivity of MeCP2 T158A mice as well as 
expression of Bdnf to test our hypothesis that MeCP2 plays a role in mediating 
pain sensitivity and confirm the functional implication of a mutation in the methyl 
binding domain.  
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MATERIALS AND METHODS 
Cell culture, transfection and luciferase reporter assay 
HEK293 and Neuro 2a cells obtained from American Type Culture Collection 
(ATCC) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum at 37°C in 5% CO2. For the reporter 
assay HEK293 cells were co-transfected with precursor miRNA or anti-miRNA 
plasmid (GeneCopoeia) and luciferase reporter plasmid containing the 3’UTR of 
Mecp2 using Lipofectamine 2000 (Life Technologies) for 48 hours. The ~8.5kb 
3’UTR sequence of Mecp2 was cloned downstream of the luciferase reporter gene 
as 4 constructs of ~2kb fragment each (GeneCopoeia). The fragment with the 
miRNA target sequence of interest (1-2210bp or 6360-8591bp) was co-transfected 
with corresponding miRNA. The Luc-Pair Duo-Luciferase assay (GeneCopoeia) 
was used to measure firefly and renilla luciferase according to the manufacturer’s 
instructions. Firefly luciferase measurements normalized to renilla was used as a 
transfection control. For monitoring changes in endogenous MeCP2, Neuro 2a 
cells were transfected with precursor miRNA or anti-miRNA plasmid 
(GeneCopoeia) using X-tremeGENE HP (Roche-biochem) for 48 hours. 
Western blot 
Protein from Neuro 2a cells or DRG was isolated using radioimmunoprecipitation 
assay buffer (Thermo Scientific). For western blotting, 20µg protein lysates were 
resolved by a 4-12% SDS–PAGE gel, transferred to the nitrocellulose membrane. 
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The membranes were probed with MeCP2 antibody [78] at 1:3000 dilution 
overnight. Chemiluminescence was detected using FluorChem M System (Protein 
Simple). The membrane was also probed with goat anti-rabbit GAPDH-HRP 
(1:2000 dilution, Santa Cruz) as a loading control. Quantification was determined 
using UN-SCAN-IT software, MeCP2 expression was normalized to GAPDH.  
Immunocytochemistry 
Neuro 2a cells grown on 12mm glass coverslips were transfected with miRNA 
precursor plasmids using X-tremeGENE HP DNA transfection reagent for 48 
hours. Cells were fixed in 4% formaldehyde and blocked in 10% NGS before a 3 
hour incubation in 1:200 anti-MeCP2 antibody (mentioned above). Anti-Rabbit-IgG 
Atto 647N secondary antibody (Sigma) was used for detection of MeCP2. 
Coverslips were mounted onto slides using Vectashield Mounting Medium with 
DAPI (Vector Laboratories). Images were acquired using the 60x objective on the 
Olympus 1X81 confocal microscope and Fluoview FV10-ASW software. Image J 
was used for quantification, MeCP2 levels were normalized to DAPI staining of the 
nucleus, then, transfected (GFP positive) and untransfected (GFP negative) cells 
were compared. 
Quantitative RT-PCR  
RNA was purified from Neuro 2a cells, DRG collected  from SNI, sham control, 
Mecp2-null, MeCP2 T158A and the corresponding wild-type littermate mice using 
the mirVana RNA isolation kit (Life technologies).  cDNA synthesis and qRT-PCR 
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were performed as previously described [101]. The Assay ID for the Taqman 
primer probes used were Mm01193535_M1 (Mecp2) and Mm04230607_s1 
(Bdnf). Gapdh was used as the normalizer and a t-test was used to perform 
statistical analysis. 
Animal model of neuropathic pain 
The care and use of all mice were approved by the Institutional Animal Care & Use 
Committee of Drexel University College of Medicine. The SNI model was 
generated using 8-week old C57BL/6 male mice (Taconic) as previously described 
[10, 102]. Briefly, mice were anesthetized with isoflurane during surgery. The 
common peroneal and tibial nerves of the left paw were ligated, 2-4mm of the nerve 
was sectioned and removed distal to ligation. Sham mice underwent the same 
surgical procedures as the SNI group without ligation and sectioning. Development 
of mechanical hypersensitivity was assessed using von Frey filaments [102] and 
the Mann-Whitney U test was used to calculate significance.  L4 and L5 DRG on 
the ipsilateral side of surgery were collected 4 weeks post SNI surgery at 12 weeks 
of age. 
Behavior studies using MeCP2 T158A mice 
Male MeCP2 T158A mice and wild-type littermates were purchased from Jackson 
laboratories (Bar Harbor, Maine). Thermal and mechanical sensitivity were 
determined using the Hargreaves’ method and von Frey filaments respectively. 
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Behavior testing and tissue collection was conducted at 12 weeks of age. Mann-
Whitney U test was used for statistical analysis. 
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RESULTS 
Chronic neuropathic pain induced MeCP2 upregulation in DRG 
MeCP2 has been predicted to play a role in pain and modulation of MeCP2 has 
been observed in various inflammatory and neuropathic pain models [82, 103]. To 
investigate whether MeCP2 expression is altered in a neuropathic pain state, we 
generated an SNI model. We confirmed increased mechanical sensitivity and data 
4 weeks post-surgery on 12 week old mice is shown in Figure 1A. Though there 
was a trend, the increase in Mecp2 mRNA in DRG after nerve injury was not 
significant (Figure 1B). However, there was a significant increase in MeCP2 protein 
in the SNI model (Figure 1C). This increased expression of MeCP2 in a 
neuropathic pain state could in part be mediated by the reduced expression of 
miRNAs predicted to target Mecp2 in the DRG [40]. We therefore sought to 
determine the regulatory role of a selected subset of miRNAs on MeCP2 
expression. 
Confirmation of miRNAs predicted to target Mecp2 3’UTR 
To experimentally validate the bioinformatics prediction of miRNAs targeting the 
Mecp2 3’UTR, a luciferase reporter assay was performed. We tested a subset of 
miRNAs that were decreased in the DRG from a nerve injury model based on seed 
sequence complementarity, varying positions throughout the 3’UTR, the presence 
of multiple binding sites, and those not predicted to target Bdnf mRNA. Reduction 
in luciferase expression and therefore, miRNA binding to the Mecp2 3’UTR was 
50 
 
validated for miR-19a, miR-301 and miR-132 (Figure 2A), while miR-17 and miR-
181 did not reduce luciferase activity (data not shown). 
MeCP2 expression is modulated by miRNAs 
To further evaluate regulation of MeCP2 expression from miRNA binding, Neuro 
2a cells were transfected with precursor miRNAs or antagomirs that are inhibitors 
of endogenous miRNAs. Our data indicate that transfection of Neuro 2a cells with 
miR-19a, miR-301 and miR-132 did not decrease Mecp2 mRNA (Figure 3A) but  
reduced MeCP2 protein as shown in western blot (Figure 3B) and 
immunocytochemistry of MeCP2 in cell transfected with individual miRNAs (Figure 
3D-F). The antagomirs of miR-301 and miR-132 increased MeCP2 expression 
(Figure 3C). We did not observe an increase in MeCP2 protein after the 
transfection of miR-19a inhibitor which could be due to a low endogenous level of 
miR-19a in Neuro 2a cells, the inhibition of which would not lead to the modulation 
of MeCP2 expression. Since we did not observe significant changes in Mecp2 
mRNA after over expressing miRNAs, we conclude that Mecp2 regulation by 
miRNAs tested is mediated by translational repression and not through RNA 
degradation. 
miRNA-mediated decrease of MeCP2 lead to concomitant reduction in Bdnf 
To determine if miRNA mediated regulation of MeCP2 affects expression of the 
MeCP2 target genes, we measured Bdnf mRNA after transfecting Neuro 2a cells 
with miR-19a, miR-301 and miR-132. Figure 4A shows that there was a reduction 
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in Bdnf transcripts after overexpressing miRNAs. Additionally, inhibiting 
endogenous miR-132 and miR-301 resulted in increased Bdnf transcript (Figure 
4B). The miRNAs used in this study were confirmed to target the Mecp2 3’UTR, 
but are not predicted to bind the Bdnf 3’UTR. Thus, the reduced expression of Bdnf 
can be a direct consequence of miRNA mediated regulation of MeCP2. 
MeCP2 T158A mice have reduced mechanical sensitivity 
Mice expressing 50% of the wild-type level of MeCP2 and female Mecp2+/- mice 
have reduced thermal sensitivity [65, 66]. We wanted to further investigate the 
effect of MeCP2 mutations on pain behavior by assessing nociception in MeCP2 
T158A mice. We observed that MeCP2 T158A mice have an age dependent 
reduction in mechanical sensitivity compared to wild-type littermate control mice 
(Figure 5A). Although thermal sensitivity changes have been reported in MeCP2 
mutant mice [65, 66], we found no significant changes in thermal sensitivity as 
determined by Hargreaves’ method between MeCP2 T158A and wild-type 
littermate control mice (Figure 5B). These results indicate a role for MeCP2 in 
mediating mechanical sensitivity. 
Bdnf is downregulated in the DRG of Mecp2-null mice and MeCP2 T158A 
mice 
Several studies using mouse models have shown a direct correlation between 
MeCP2 and Bdnf expression in the brain indicating that MeCP2 regulates Bdnf 
[95]. We examined Bdnf expression in DRG from Mecp2-null mice. Figure 6A 
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shows a reduction in Bdnf mRNA levels in Mecp2-null mice compared to control. 
Thus MeCP2 mediated regulation of Bdnf expression in DRG appears to be similar 
to that observed in brain. We then investigated Bdnf levels in DRG from MeCP2 
T158A mice to determine if a loss of function mutation would yield a similar result 
(Figure 6B). We observed a decrease in Bdnf mRNA in the DRG of MeCP2 T158A 
mice as was previously reported in the brain [78]. These results indicate that in 
DRG, the role of MeCP2 as an activator is important for precise regulation of Bdnf 
and alteration of Bdnf in DRG may be a contributing factor leading to aberrant pain 
sensitivity in RTT.  
Bdnf is decreased in MeCP2 T158A SNI model compared to wild-type SNI 
model mice 
To determine how changes in MeCP2 in the DRG affect pain behavior, we 
generated an SNI model with MeCP2 T158A mice and wild-type littermate controls. 
Unfortunately, conducting mechanical and thermal sensitivity assessment post 
SNI surgery was not possible in the MeCP2 T158A mouse; post-surgical over 
grooming behavior resulted in further physical disability compared to wild-type 
littermates. We collected the DRG from MeCP2 T158A mice 4-weeks post SNI and 
from wild-type SNI mice, and measured Bdnf transcripts. After nerve injury, MeCP2 
T158A mice have decreased Bdnf compared to wild-type littermate control mice 
(Figure 6C). This suggests that in the absence of fully functional MeCP2, the 
upregulation of Bdnf is impaired even after nerve injury, again suggestion a 
regulatory role of MeCP2 on Bdnf. 
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DISCUSSION 
The role of MeCP2 in the development and function of the central nervous system 
is well established and neuronal dysfunction contributes to symptoms associated 
with RTT [66, 92]. Previous studies investigating the role of MeCP2 in pain have 
shown differences in expression pattern of MeCP2 in DRG and spinal cord from 
various rodent models of pain. An increase in MeCP2 has been associated with 
the development of neuropathic pain in the chronic constriction injury model in rats 
14 days after injury [56]. MeCP2 is known to play an important role in signaling in 
the superficial dorsal horn upon induction of peripheral inflammation by injecting 
complete Freund’s adjuvant (CFA) in rat ankle joint. This study showed that 
phosphorylation of MeCP2 led to the release of DNA-bound MeCP2, relieving the 
repression on a few MeCP2 target genes in lamina I neurons. These genes were 
upregulated rapidly in this model of inflammatory pain [72]. MeCP2 expression was 
increased in the superficial dorsal horn 7 days following CFA injection in the ankle 
joint but decreased 7 days following SNI [71]. This study also showed that MeCP2 
levels were decreased in activating transcription factor 3 (ATF3)-positive neurons 
in DRG after SNI [71]. Another report showed an increase in Mecp2 transcripts in 
the spinal cord 2 hours after peripheral injection of formalin [51]. Upregulation of 
MeCP2 in the central nucleus of the amygdala was reported in the CFA model [73]. 
Differences in models, tissues, and time points can influence gene expression and 
so we performed qPCR and western blot analysis for MeCP2 using DRG from a 
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mouse SNI model of neuropathic pain 4 weeks after surgery. We observed an 
increase of MeCP2 protein in DRG.  
MeCP2 can epigenetically regulate miRNAs [104] and dysregulation of 
miRNAs was observed in the cerebella of Mecp2-null mice [105]. miRNA-mediated 
alteration of MeCP2 was reported to alter pain threshold in wild-type mice. miR-
124a was downregulated in spinal cord after peripheral noxious stimulation with 
formalin and this was associated with an increase in Mecp2 mRNA [51]. 
Intravenous administration of a miRNA-124a inhibitor enhanced the nociceptive 
behavior and miRNA-124a mimic significantly reduced formalin-induced 
inflammatory pain. In addition to confirming that Mecp2 is a target for miR-124a, 
this study showed administration of miR-124a mimic induced a decrease in Mecp2 
mRNA and miR-124a inhibitor enhanced MeCP2 levels in the spinal cord [51]. In 
another study, intrathecal miR-124 treatment reversed persistent hyperalgesia 
induced by carrageenan and prevented the development of mechanical allodynia 
in the SNI model of chronic neuropathic pain [50]. Thus future studies investigating 
the role of miRNAs validated to target Mecp2 will be beneficial in confirming their 
role in pain. 
Our previous study investigating miRNA changes in DRG identified several 
miRNAs predicted to target Mecp2 3’UTR. The miRNAs were downregulated after 
nerve injury and because of the expected inverse correlation in expression 
between miRNAs and genes they regulate, we selected a subset of 5 miRNAs for 
further studies. Of these, miR-19a, miR-301 and miR-132 were confirmed to bind 
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and regulate Mecp2 by translational repression. miR-132 is a previously validated 
miRNA for MeCP2 [79] and we included it as a positive control. This reduction of 
MeCP2 protein resulted in decreased Bdnf, indicating that activation by MeCP2 is 
an important regulatory mechanism for normal expression of BDNF. Our findings 
that inhibition of miRNA-mediated repression increased MeCP2 and Bdnf is similar 
to what was reported for miR-132 in cultured rat neurons [79]. 
Alterations in BDNF expression is a common phenomenon in both RTT and 
pain states, albeit in reverse direction. BDNF is an important modulator of sensory 
neurotransmission in nociceptive pathways both at spinal and supraspinal levels 
and has an important role in the development of central sensitization that underlies 
many forms of hyperalgesia [96]. Many of the biological effects of BDNF are 
mediated by the high affinity postsynaptic receptor Tropomyosin receptor kinase 
B (TrkB). TrkB signaling contributes to both the induction and maintenance of injury 
induced persistent pain [106] and Trk inhibitors have been developed for the 
treatment of pain [107]. In addition to correlation of BDNF levels in the 
hypothalamus with MeCP2 levels, with lower levels in Mecp2-null mice and higher 
levels in MECP2 overexpressing mice compared to controls [31], disruption of total 
BDNF  levels and secretion in Mecp2-null neurons indicate that functional MeCP2 
is important for BDNF expression [108]. BDNF-related therapies have shown a 
reversal of cardiorespiratory deficits in Mecp2-null mice and is being pursued for 
the amelioration of RTT-like neurological symptoms in mouse models [95]. Our 
qPCR studies showed that Bdnf levels in the DRG were downregulated in both 
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Mecp2-null and MeCP2 T158A mice. Thus the reduction in endogenous Bdnf could 
be one of the contributing factors leading to decreased pain sensitivity. 
Furthermore, after SNI surgery, MeCP2 T158A mice maintained lower Bdnf levels 
than wild-type mice. This indicates that increased Bdnf in the DRG after nerve 
injury is in part mediated by MeCP2. A recent study investigating the role of MeCP2 
in pain regulation and morphine reward showed that MeCP2 and histone 
dimethyltransferase G9a induce a transcriptional de-repression of Bdnf in central 
nucleus of the amygdala, promoting pain behavior through BDNF upregulation 
[73]. Thus in addition to direct activation of Bdnf, MeCP2 in its role as a 
transcriptional repressor of G9a, further enhance BDNF levels in chronic pain. 
Our studies showed that mice with the loss of function mutation, T158, have 
reduced mechanical sensitivity compared to wild-type littermates. Previous studies 
have shown that different MeCP2 mutant mouse lines, including Mecp2Flox/y mice 
expressing 50% of the wild-type level of MeCP2 and female Mecp2+/- mice have 
reduced thermal sensitivity [65, 66] but the mechanical sensitivity was not 
investigated in these mutant mice. Our assessment of thermally induced 
nociception showed no differences in MeCP2 T158A mice and wild-type 
littermates. This could be due to the specific mutation of MeCP2, or the 
methodology used to assess thermal sensitivity.  Since BDNF release in dorsal 
horn in neuropathic pain model is associated with thermal hyperalgesia, [109, 110], 
we postulate that other modes of action may be playing a role in mediating 
mechanical sensitivity in T158A mice. Studies investigating function of DRG 
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neurons in naïve rodents have shown that delivering BDNF directly to DRGs 
induced mechanical allodynia, conversely, after nerve injury direct administration 
of anti-BDNF antibody to injured DRG attenuated mechanical allodynia [111]. 
MeCP2 and BDNF are expressed in microglia and astrocytes in addition to 
neurons [112] and additional studies are needed to determine the contribution of 
these different cell types in modulating aberrant pain sensation in MeCP2 T158A 
mice. A recent study investigated the role of miR-183, a miRNA that was 
significantly downregulated in the ipsilateral L5 DRG after SNL [113]. Intrathecal 
administration of miR-183 attenuated mechanical allodynia and this was 
associated with the downregulation of BDNF transcripts in DRG [113]. This study 
demonstrated that downregulation of BDNF in DRG was correlated with attenuated 
mechanical allodynia in SNL model of neuropathic pain. Our data shows that 
mutations in Mecp2 can reduce mechanical pain sensitivity. Since MeCP2 can 
mediate downstream transcriptional changes of a large number of genes, we 
acknowledge the likely contribution of other dysregulated genes to aberrant pain 
sensitivity in MeCP2 T158A mice. Additional studies are needed to assess how 
altered gene expression resulting from the weaker DNA binding properties of 
MeCP2 with the T158A mutation [78] can influence mechanical but not thermal 
sensitivity in the T158A KI mice. 
In conclusion, our results indicate that miRNA-mediated regulation of 
MeCP2 can contribute to the mechanical hypersensitivity observed in neuropathic 
pain models by altering BDNF. Neuropathic pain induces MeCP2 and BDNF 
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expression in the DRG; conversely, RTT mouse models lacking or expressing 
reduced levels of MeCP2 have decreased Bdnf that can contribute to mechanical 
hyposensitivity. Further investigations including in vivo delivery of miRNAs 
targeting Mecp2 followed by characterization of pain behavior and investigation of 
MeCP2 expression and downstream targets in naïve mice, RTT and pain models 
can provide insights on therapeutic options for both pain and RTT. 
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CHAPTER 2: Figure legends and Figures 
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Figure 1: MeCP2 expression in DRG 4 weeks after SNI or sham surgery 
 A, von Frey filaments used to assess paw withdrawal threshold confirmed that 
mice were hypersensitive 4 weeks post SNI surgery (n=10). Significance was 
determined using Mann-Whitney U test p value <0.001. B, Taqman analysis of 
Mecp2 mRNA showed a trend toward increased expression that was not significant 
in SNI model compared to sham control (n=7). Gapdh was used as the normalizer. 
C, Western blot analysis of MeCP2 expression in DRG showed a significant 
increase in SNI model, determined using Student’s t-test, p value *<0.05. Tissue 
from 9 animals was pooled into 3 samples (n=3). Protein expression was 
normalized to GAPDH. 
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Figure 2: miRNA binding to MeCP2 3’UTR  
Luciferase assay showing miR-19a, miR-301 and miR-132 binding to the 3’UTR of 
Mecp2. The luciferase activity was measured 24 hours after miRNA transfection. 
The data expressed as percentage of control is the average of 3 independent 
experiments. Statistically significant difference from control was calculated using 
one way ANOVA and Student’s t-test, p value **<0.01, ***<0.001. 
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Figure 2 
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Figure 3: Regulation of MeCP2 by miRNAs 
A, Taqman analysis of Mecp2 in Neuro 2a cells 48 hours after miRNA transfection 
showed no significant reduction in mRNA (n=3). B, Western blot analysis after 
transfection of Neuro 2a cells with miR-19a, miR-301 and miR-132 significantly 
reduced MeCP2 protein (n=3). C, MeCP2 expression increased when cells were 
transfected with anti-miR (miRNA inhibitors) for miR-301 and miR-132; (n=3, 
representative blot shown). D,E, Immunocytochemisty for MeCP2 in Neuro 2a cells 
transfected with miR-132. MeCP2 levels were normalized to DAPI staining of the 
nucleus and graphically represented as expression relative to untransfected cells. 
Representative images are shown, n=3. F,G, Immunocytochemistry and 
quantification for miR-19a transfected cells. H,I, Immunocytochemistry and 
quantification for miR-301 transfected cells. Significance was determined using 
Student’s t-test, p value *<0.05, **<0.001 ***<0.001.  
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Figure 4: MeCP2 mediated changes in Bdnf transcripts.  
A, miRNA-mediated reduction of MeCP2 expression decreases Bdnf mRNA in 
Neuro 2a cells 48 hours after miRNA transfection as determined by Taqman 
analysis, and B, Antagomirs, inhibitors of endogenous miRNAs, increase Bdnf 
mRNA. Gapdh was used as the normalizer, n=3. Significance determined using 
Student’s t-test p value *<0.05, **<0.001. 
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Figure 4 
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Figure 5: MeCP2 T158A knock in mice have decreased mechanical 
withdrawal threshold.  
A, Mechanical sensitivity measured by von Frey filaments showed an increase in 
withdrawal threshold in MeCP2 T158A KI mice, indicating hyposensitivity 
compared to wild-type littermate controls. B, Thermal sensitivity was unchanged 
between MeCP2 T58A KI mice and wild type littermates (n=5 for MeCP2 T158A 
mice and n=7 for wild-type littermate mice). Statistically significant difference was 
determined using the Mann-Whitney U test confirming significant reduction in 
withdrawal threshold in the ipsilateral paw p value **<0.01, ***<0.001. 
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Figure 5 
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Figure 6: Downregulation of Bdnf expression in Mecp2 mutant mice 
A, DRG from Mecp2-null mice and B, MeCP2 T158A mice has significantly lower 
Bdnf mRNA compared to wild-type littermates, n=3.  (n=6). C, Bdnf was also lower 
in the MeCP2 T158A mice compared to wild-type littermates after SNI surgery. 
Significance determined using Student’s t-test, p value *<0.05. 
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CHAPTER THREE: MeCP2 Mediated Regulation of Genes 
Involved in Pain in the Dorsal Root Ganglia 
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ABSTRACT 
Methyl-CpG-binding protein 2 (MeCP2), a protein with affinity for methylated 
cytosines, is crucial for neuronal development and function. MeCP2 regulates 
gene expression through activation, repression and chromatin remodeling. 
Mutations in MECP2 cause Rett syndrome (RTT) and these patients display 
impaired nociception. We observed an increase in MeCP2 expression in mouse 
dorsal root ganglia (DRG) after peripheral nerve injury. The functional implication 
of increased MeCP2 is largely unknown. To identify regions of the genome bound 
by MeCP2 in the DRG and the changes induced by nerve injury, MeCP2 ChIP-seq 
was performed. While the number of binding sites across the genome remained 
similar in the spared nerve injury (SNI) model and control, SNI induced the 
redistribution of MeCP2 to transcriptionally relevant regions. To determine how 
differential binding of MeCP2 can affect gene expression in the DRG, we 
investigated mmu-miR-126, a microRNA locus that had enriched MeCP2 binding 
in the SNI model. Repression of miR-126 expression and the ensuing downstream 
molecular changes in the DRG after nerve injury was confirmed using the SNI 
model, Mecp2-null mice and a neuronal cell line. Our study shows a regulatory role 
for MeCP2 in that, changes in global redistribution can result in direct and indirect 
modulation of gene expression in the DRG, thereby contributing to epigenetic 
alterations underlying nerve injury. 
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INTRODUCTION 
Epigenetic modifications resulting from DNA methylation plays a critical role in 
cellular differentiation, development [32], and may contribute to disease including 
peripheral and central pain sensation and processing [59]. DNA methylation is 
mediated by DNA methyltransferase (DNMT) catalyzing the transfer of a methyl 
group onto the 5′ position of cytosine. MeCP2 can decipher methylation patterns 
across the genome before binding to methylated DNA [32], and can mediate 
downstream transcriptional changes of a large number of genes [31]. Depending 
on its interacting protein partners and target genes, MeCP2 can act either as an 
activator or repressor [94]. MeCP2 can also play a role in dampening genome-
wide transcriptional noise in a DNA methylation-dependent manner [28]. Mutations 
in MECP2 result in the neurodevelopmental disorder RTT [114]. Among the many 
symptoms associated with RTT, alterations in pain sensitivity are reported to be as 
high as 75% [63]. Reduced sensitivity has been observed in mouse models with 
RTT and autism-associated mutations [64-67]. The observations from RTT 
patients and MeCP2 mutant mice indicate that MeCP2 contributes either directly 
or indirectly to reduced pain sensitivity.  
Our previous study has shown that MeCP2 expression was altered in 
mouse DRG following SNI. While we observed upregulation 4 weeks post-surgery 
[64], others have reported downregulation at earlier time points and in subsets of 
damaged neurons in the DRG [67, 71]. MeCP2 has previously been linked to 
inflammatory pain.  Inflammatory stimulus was shown to increase phosphorylation 
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of MeCP2 in lamina I neurons in the dorsal horn, resulting in its dissociation from 
the genome, thereby alleviating repression of genes linked to pain [72]. MeCP2 
has also been associated with central mechanisms of pain through regulation of a 
transcriptional repressor, histone dimethyltransferease G9a, resulting in increased 
expression of brain-derived neurotrophic factor [73].  
MeCP2 is highly expressed in neurons and glia [28]. The dynamic 
expression of MeCP2 in the DRG after nerve injury [64] suggests a role for MeCP2 
in pain modulation through transcriptional regulation. DRG is a major player 
responsible for conveying noxious stimuli from the periphery to the central nervous 
system. MeCP2 is predominantly a nuclear protein and cell bodies of nociceptive 
sensory neurons are located in DRG, with two axonal branches projecting to the 
periphery and to the dorsal horn of the spinal cord. Genome-wide studies 
investigating MeCP2 binding patterns have been conducted in neurons, astrocytes 
and different regions of the brain [28, 115-117]. To investigate the role of MeCP2 
in mediating nociception, and to determine changes in MeCP2 binding patterns 
after nerve injury, we performed ChIP-seq in mouse DRG 4 weeks after SNI 
surgery. We observed a genome-wide redistribution of MeCP2 binding, and 
evaluated how changes in binding patterns directly and indirectly affect gene 
expression that contributes to the pathology of pain. 
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MATERIALS AND METHODS 
Animal model of neuropathic pain 
The care and use of all mice were approved by the Institutional Animal Care & Use 
Committee of Drexel University College of Medicine. The SNI model was 
generated using 8-week old C57BL/6 male mice (Taconic) as previously described 
[10, 102]. Briefly, mice were anesthetized with isoflurane during surgery. The 
common peroneal and tibial nerves of the left paw were ligated, 2-4mm of the nerve 
was sectioned and removed distal to ligation. Sham mice underwent the same 
surgical procedures as the SNI group without ligation and sectioning. Development 
of mechanical hypersensitivity was assessed using von Frey filaments [102].  L4, 
L5 and L6 DRG on the ipsilateral side of surgery were collected 4 weeks post SNI 
surgery at 12 weeks of age.  
Mecp2-null mice 
DRG from approximately 12 weeks old male hemizygous Mecp2-null (Mecp2-/y) 
mice and wild type littermates (Mecp2+/y) were collected for molecular 
characterization [77]. These mice do not have detectable Mecp2 gene product and 
were used to study gene expression in the absence of MeCP2. 
Chromatin immunoprecipitation (ChIP) of MeCP2 
ChIP was performed using protocols adapted from Covaris truChIP chromatin 
shearing kit tissue SDS and Millipore magna ChIP G tissue kits. Ipsilateral L4, L5 
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and L6 DRG were collected 4-weeks after SNI or sham surgery. DRG was pooled 
from 10 mice per sample, in duplicates. Samples were washed 3 times in 
phosphate buffered saline (PBS) containing protease inhibitors (PI). Chromatin 
was crosslinked to DNA using 1% methanol-free formaldehyde and incubated at 
room temperature for 5 min with rotation. Samples were then incubated with 
Covaris quenching buffer for 5 min at room temperature with rotation to quench 
the formaldehyde crosslinking reaction. Samples were washed 3 times for 5 min 
with PBS containing PI. Tissue samples were resuspended in Covaris lysis buffer 
containing PI, incubated on ice for 10 min and homogenized by pipetting. After 10 
min incubation on ice, nuclei were pelleted at 1700xg for 5 min at 4°C. Samples 
were washed using 1ml Covaris wash buffer, pellets resuspended in 130µl Covaris 
SDS shearing buffer containing PI and incubated on ice for 10 min. Chromatin was 
sheared using the Covaris M220. Insoluble material was pelleted by centrifugation 
at 10,000xg for 5 min. Five µl of the supernatant was removed for Input samples. 
To each sample, 20µl of Protein G magnetic beads and 5µl anti-MeCP2 antibody 
[78] or 5µl rabbit serum was added and incubated overnight at 4°C with rotation. 
Beads were pelleted with a magnetic separator, washed and resuspended in 
Millipore elution buffer containing proteinase K, followed by incubations at 62°C 
overnight, and 95°C for 10 min.  Supernatant was used for DNA purification 
according to manufacturer’s instructions. 
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Sequence Alignment and Filtering 
Single-end 50 base reads were generated on the Applied Biosystems (AB) SOLiD 
5500xl platform. Reads were mapped to the mm10 genome using AB LifeScope 
2.5.1 software.  Reads in each sample were filtered out based on their mapping 
quality, to eliminate poorly mapping reads and reads that may map to multiple 
places in the genome, and only reads MAPQ≥10 were used for peak calling and 
tag enrichment analysis.  Samtools [118] merge was used to pool replicates for 
each IP condition, and samtools rmdup was used to remove duplicate reads so 
that only unique tags were used for peak calling.  
Peak Calling 
The HOMER (Hypergeometric Optimization of Motif EnRichment) suite [119] was 
used for peak calling on the sham and SNI IP sequence libraries, using respective 
sham and SNI input libraries as control.  HOMER ChIP-seq tag directories were 
created from the set of unique mapped reads for each IP and input condition.  
HOMER peak calling (findPeaks) was performed for both narrow peaks (-style 
factor) and broad peaks (-style histone).  Visual review of the sequence tags in the 
Integrated Genomics Viewer (IGV) [120] was used to decide whether narrow or 
broad peaks were a better fit for MeCP2 binding patterns.  The set of broad peaks 
was selected as the better representation of MeCP2 binding and used for 
subsequent annotation and interpretation. HOMER was also used to identify 
differential binding between sham and SNI, using the getDifferentialPeaks tool, 
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with default settings to identify peaks with 4-fold more tags in one condition versus 
the other, with p-value less than 0.0001.  
Annotation 
The HOMER annotation database v5.4 for mouse was used in conjunction with the 
HOMER annotation tool (annotatePeaks) to identify the closest genomic feature to 
each peak, as well as enrichment statistics for genomic regions including 
promoters, exons, introns, intergenic regions, etc.  Annotation was performed on 
the set of all sham peaks, all SNI peaks, as well as differentially bound peaks in 
sham and SNI. The HOMER annotatePeaks tool was also used in mRNA and 
miRNA mode to analyze tag enrichment and peak locations with respect to all 
annotated genes and miRNAs.   
Cell culture and transfection  
Neuro 2a cells obtained from American Type Culture Collection (ATCC) were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum at 37°C in 5% CO2. For monitoring changes in 
endogenous Dnmt1 and Vegfa expression, cells were transfected with precursor 
miR-126 plasmid (GeneCopoeia) using X-tremeGENE HP DNA transfection 
reagent (Roche) for 72 hours. 
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Quantitative RT-PCR 
RNA was purified from the following samples: Neuro 2a cells, DRG collected from 
SNI model, sham control, Mecp2-null and wild-type littermate mice using the 
mirVana RNA isolation kit (Life technologies).  cDNA synthesis and qRT-PCR for 
mRNA were performed as previously described [101]. The Assay ID for TaqMan 
primer probes used were Mm00599780_g1 (Dnmt1) and Mm00437306_m1 
(Vegfa). Gapdh was used as a normalizer. cDNA synthesis for miR-126 and 
detection was conducted using TaqMan microRNA assay (Assay ID 00451, 
Applied Biosystems). U6 was used for normalization.  
Western blot 
 Protein from Neuro 2a cells or DRG was isolated using radioimmunoprecipitation 
assay buffer (Thermo Scientific). For western blotting, 2µg protein lysate from DRG 
or 10µg from cell pellets were resolved by a 4-12% SDS–PAGE gel, transferred to 
nitrocellulose membrane. The membranes were probed with 1:500 dilution of 
Dnmt1 (D63A6) XP antibody #5032 (Cell Signaling) or 1:1000 Vegfa antibody 
(Abcam ab51745) overnight at 4°C. Chemiluminescence was detected using 
FluorChem M System (Protein Simple). The membrane was also probed with 
1:1000 β tubulin (9F3) antibody #2128 (Cell Signaling) as a loading control. 
Quantification was done using UN-SCAN-IT software, Dnmt1 and Vegfa 
expression was normalized to β tubulin.  
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Immunocytochemistry 
Neuro 2a cells grown on 12mm glass coverslips were transfected with miRNA 
precursor plasmids with GFP using X-tremeGENE HP DNA transfection reagent 
for 72 hours. Cells were fixed in 4% formaldehyde and blocked with 10% normal 
goat serum followed by a 3 hour incubation in 1:500 anti-Dnmt1 antibody 
(mentioned above). Anti-Rabbit-IgG Atto 647N secondary antibody (Sigma) was 
used for detection of Dnmt1. Coverslips were mounted using Vectashield mounting 
medium with DAPI (Vector Laboratories). Images were acquired using the 60x 
objective on the Olympus FV1000 confocal microscope and Fluoview FV10-ASW 
software.  Transfected (GFP positive) and untransfected (GFP negative) cells were 
compared.  
Intrathecal catheter implantation and miRNA injection 
miRNA administration protocol was adapted from previous reports of intrathecal 
miRNA delivery [39]. To administer miRNA mimics, a polyurethane catheter (25G, 
5.5cm long, SAI-infusion) was placed into the intrathecal space of the lumber L4-
L5 vertebrae under isoflurane anesthesia. The catheter was stereotactically 
secured under the skin, and occluded between injections. A custom miRCURY 
(Exiqon) miR-126 mimic containing a 5’ cholesterol tag and 3’ fluorescein label 
was injected at 2nmol concentration with 4µl iFECT transfection reagent 
(Neuromics). A total of 6µl was delivered into the catheter connection juncture 
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using a 25G blunt end needle on a Hamilton syringe. The catheter was then flushed 
with 7µl sterile PBS to ensure miRNA reached the intrathecal space.  
Bisulfite sequencing and analysis of CpG sites in miR-126 locus 
To analyze the methylation status of CpG dinucleotides in the miR-126 locus, L4, 
L5 and L6 DRG were collected from 3 SNI or 3 sham control mice four weeks after 
surgery. Mouse genomic DNA was isolated using GenElute mammalian genomic 
DNA minipreps kit (Sigma Aldrich) and subjected to bisulfite conversion using the 
Epitect fast DNA bisulfite kit (Qiagen). The 72bp fragment of interest was amplified 
using the following primer pairs designed with MethPrimer software [121]; Forward: 
TATTTTGAAGAGGTTTTTGGAAGG, 
Reverse: CCAAAACACACAACTAACTAAAAACAA.  
Statistical methods 
For statistical analysis, mean values with standard error are shown; p values were 
determined using Student’s t-tests with paired or unpaired samples, significance 
was set at p <0.05. 
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RESULTS 
MeCP2–DNA binding profiles 
To determine nerve injury induced changes in MeCP2-bound chromatin, we 
conducted ChIP-seq in the DRG from SNI model and sham control mice. 
Generation of SNI model, confirmation of  hypersensitivity and DRG collection 4 
weeks post-surgery have been previously described [64]. ChIP-seq was 
conducted on DRG pooled from 10 mice per sample. We determined that MeCP2 
binding occurred broadly across the genome, as previously reported [28, 117]. 
Enriched binding was observed in promoter regions and gene bodies for both 
protein coding and noncoding genes in SNI and sham control DRG (Figure 1A-C).  
Comparison of MeCP2-bound sequences at single base resolution indicates 
distinct and common MeCP2 binding sites to regions encoding mRNAs in SNI and 
sham DRG samples (Figure 1D).  
Genome-wide redistribution of MeCP2 binding in the DRG after nerve injury  
Comparative analysis of enriched peaks in SNI versus sham was done to elucidate 
nerve injury induced differences in genome-wide MeCP2 binding.  A redistribution 
of MeCP2 binding in SNI as indicated by increased enrichment within transcribed 
regions, is shown in Figure 2A-B.  Table 1 shows ten genes with enriched MeCP2 
binding in the promoter and in the gene bodies that have a four-fold increase or 
decrease (log2 fold change) between sham and SNI, with p < 0.001. Distinct 
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binding patterns of MeCP2 in SNI could therefore lead to alterations in the genome, 
which in turn can mediate gene expression changes ensuing nerve injury. 
Enriched MeCP2 binding to miRNAs 
We then investigated changes in MeCP2 binding to miRNAs after nerve injury. 
While miRNA-transcribed regions represent a much smaller fraction of the genome 
compared to protein-coding genes, our analysis highlighted a small number of 
miRNA loci with distinct MeCP2 binding pattern. A subsequent analysis of MeCP2-
bound sequence tags indicated that miRNA regions were enriched for MeCP2 
binding, and this enrichment was observed in the SNI model (Figure 3A). However, 
MeCP2 binding for several miRNA regions was detected in only one condition, 
sham or SNI, indicating different regulatory profiles in SNI versus sham.  The 
miRNAs most enriched for MeCP2 binding, including 14 miRNAs with increased 
MeCP2 binding and 21 miRNAs with decreased binding in the SNI model relative 
to sham, are shown in Figure 3B. Of all the miRNAs with enriched MeCP2 binding, 
miR-126a and miR-126b have the largest fold enrichment in the SNI model. 
Therefore, we pursued further characterization of enriched MeCP2 binding to the 
miR-126 locus in the SNI model. 
miR-126 locus has enriched MeCP2 binding in SNI  
The peak profile for miR-126 locus from ChIP-seq shows enrichment for MeCP2 
binding over input control and sham samples (Figure 4A). We observed an 
enrichment of MeCP2 binding to miR-126 locus after nerve injury, with virtually no 
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binding in the sham sample. This indicates that nerve injury induced an increase 
in MeCP2 binding to miR-126 locus and hence, we further explored the functional 
consequences of this binding in the context of nerve injury induced pain. 
Methylation of miR-126 locus 
Cytosine methylation of CpG dinucleotides is recognized as a crucial epigenetic 
modification. Since MeCP2 is a methyl DNA binding protein, we wanted to 
investigate whether increased MeCP2 binding to miR-126 locus observed in the 
DRG from SNI model, was due to changes in methylation pattern. Our analysis of 
the 72 bp sequence of premiR-126 locus revealed the presence of 6 CpG sites. 
To evaluate whether SNI surgery caused alterations in the methylation status of 
premiR-126 locus, we performed bisulfite sequencing of DRG genomic DNA 
obtained from SNI and sham control mice 4 weeks after surgery. Our analysis of 
the methylation status showed that all 6 CpG sites were methylated in both SNI 
and sham samples (Figure 4B). This identical methylation patterns in SNI and 
sham control mice indicates that nerve injury did not alter the methylation status of 
premiR-126 locus. Since there was an increase in MeCP2 bound to premiR-126 
after nerve injury, we postulate that MeCP2 redistribution throughout the genome, 
and the specific enrichment at miR-126 could be induced by alterations in the 
availability of the genome for MeCP2 binding, after nerve injury.  
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miR-126 regulates expression of Dnmt1 and Vegfa in Neuro 2a cells  
The Neuro 2a mouse neuroblastoma cell line was used to investigate regulation of 
target gene expression by miR-126. Previous studies have demonstrated direct 
binding of miR-126 to the 3’UTR of vascular endothelial growth factor (Vegfa) [118] 
and DNA methyltransferase 1 (Dnmt1) [122]. Neuro 2a cells were transfected with 
miR-126 precursor plasmid, or scrambled miRNA control, expressing GFP. We 
observed a decrease in mRNA (Figure 5A) and protein levels (Figure 5B) of Dnmt1 
and Vegfa 72 hours after miR-126 transfection. We also show that miR-126 
transfected cells have decreased Dnmt1 expression compared to untransfected 
cells (Figure 5C). Based on the decrease in both transcript and protein levels, we 
conclude that miR-126 regulates expression of both Dnmt1 and Vegfa through 
degradation of mRNA. 
Repression of miR-126 and upregulation of its target genes in SNI model 
We next sought to determine the consequence of increased MeCP2 binding to 
miR-126 locus in the DRG after nerve injury. There was a significant decrease of 
miR-126 in the DRG after SNI (Figure 6A). This indicates that increased binding of 
MeCP2 represses transcription of miR-126. We hypothesized that reduced levels 
of miR-126 would result in increased expression of miR-126 target genes in the 
DRG. An increase in Dnmt1 and Vegfa transcripts were observed in the SNI model 
(Figure 6B-C). Western blot analysis confirmed an increase in Dnmt1 protein 
(Figure 6D). However, we did not observe significant changes in Vegfa protein in 
92 
 
the DRG (Figure 6E). Previous studies have shown that peripheral nerve injury 
leads to upregulation of Vegfa in accumulating neutrophils and macrophages in 
the peripheral nerve [123]. Vegfa is a secreted protein, therefore, protein 
expression in the DRG may not reflect miR-126 mediated regulation of Vegfa. 
Based on our in vitro data and reduced transcript levels of both target genes in the 
DRG after SNI, we conclude that downregulation of miR-126 levels resulting from 
MeCP2 binding, can contribute to the upregulation of Dnmt1 and Vegfa after nerve 
injury. 
Expression of miR-126 and target genes Dnmt1 and Vegfa in DRG from 
Mecp2-null mice 
To further confirm the regulatory role of MeCP2 on miR-126 expression, we 
obtained DRG from Mecp2-null mice. We assessed miR-126 levels in Mecp2-null 
mice and found that there was no significant differences compared to wild type 
littermates (Figure 7A).  This finding, along with our observation from the SNI 
model indicates that MeCP2 does not regulate expression of miR-126 under naïve 
conditions. However, there was increased MeCP2 binding to miR-126 upon nerve 
injury, resulting in miR-126 repression. Since miR-126 is a negative regulator of 
Dnmt1 and Vegfa, we wanted to investigate if MeCP2 can also affect expression 
of these genes. Thus, we assessed mRNA levels of Dnmt1 and Vegfa in the DRG 
of Mecp2-null mice to determine the regulatory role of MeCP2. These mice do not 
have detectable levels of MeCP2. Our qPCR results showed a downregulation of 
Dnmt1 (Figure 7B) and Vegfa (Figure 7C) in the DRG in the absence of MeCP2, 
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suggesting that MeCP2 may directly or indirectly regulate the activation of these 
genes. 
Overexpression of miR-126 in vivo did not alter pain threshold but decreased 
target gene expression 
We observed regulation of Dnmt1 and Vegfa by miR-126 in Neuro 2a cells, and an 
inverse correlation in expression of miR-126 and its target genes in the DRG after 
nerve injury. To investigate whether upregulation of miR-126 can alter pain 
threshold in SNI model mice, we overexpressed miR-126 by intrathecal 
administration.  An intrathecal catheter was implanted 4 weeks after SNI surgery, 
to allow for repeated administration of 2 nmol miR-126 or control miRNA. We did 
not observe a change in mechanical (Figure 8A) or thermal (data not shown) 
hypersensitivity in these mice, after overexpressing miR-126. With lack of efficacy 
in pain behavior studies, we wanted to confirm miR-126 delivery to the DRG, and 
investigate changes in Vegfa and Dnmt1 expression. Over 5 fold higher levels of 
miR-126 was detected in the DRG from mice that received miR-126 compared to 
those injected with control miRNA (Figure 8B), thus confirming uptake of miR-126 
by the DRG. Additionally, delivery of miR-126 robustly downregulated Dnmt1 and 
Vegfa mRNA in the DRG (Figure 8C). These results indicate that though the 
delivery of miR-126 decreased Dnmt1 and Vegfa expression in the DRG, this was 
not sufficient to reverse nerve injury induced mechanical and thermal 
hypersensitivity.  
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DISCUSSION 
This study provides evidence indicating that peripheral nerve injury induces 
redistribution of MeCP2 binding in the DRG. MeCP2 is implicated in pain because 
of the abnormal thresholds observed in RTT patients [63]. Studies assessing the 
pain threshold of mice with aberrant MeCP2 expression, mimicking those observed 
in patients, have shown reduced sensitivity [64-67]. Collectively, these studies 
indicate that precise regulation of MeCP2 levels is crucial for normal pain 
thresholds. We had previously observed an upregulation of MeCP2 in the DRG 4 
weeks after SNI. DRG neurons have been the focus of much research to identify 
molecular targets of pain neurotransmission because they represent primary sites 
for pain processing. Our data show that increased MeCP2 expression after 
peripheral nerve injury can induce differential binding of MeCP2 to the genome. 
This may play a crucial role in bringing about either direct or indirect global gene-
regulatory changes associated with a chronic pain state. 
MeCP2 was originally characterized for its high affinity for methylated 
cytosines that are followed by a guanine nucleotide (mCG) [32]. MeCP2 binds 
broadly throughout the genome in a DNA methylation-dependent manner. It is now 
known that MeCP2 can bind two alternatively methylated forms of DNA including 
methylated cytosine followed by a nucleotide other than guanine (mCH, where H 
= A, C or T) and hydroxymethylcytosine (hmC) [22, 23]. Both mCH and hmC are 
enriched in human and mouse brain but there are no reports to date on the status 
of these alternately methylated forms of DNA in the DRG. In general, mCH appears 
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to be a repressive mark that inhibits gene expression [22, 124]. The occurrence of 
hmC within gene bodies however, has been associated with active gene 
expression in neurons [23, 124]. Our ChIP-seq data suggests a genome-wide shift 
in the binding pattern of MeCP2 after nerve injury, including three thousand distinct 
mRNA encoding sites. There also seems to be a redistribution from binding at 
intergenic regions to an overall increase in binding to transcriptionally relevant 
regions and non-coding RNAs. MeCP2 quantification in postmitotic neurons 
showed that it is nearly as abundant as the histone octamer. It was suggested that 
genome-wide binding of MeCP2 in a DNA methylation-dependent manner may 
dampen transcriptional noise and MeCP2 may contribute to the basic structure of 
neuronal chromatin [28]. MeCP2 was shown to modulate transcription in a gene-
length-dependent manner and preferential upregulation was observed for long 
genes enriched for methylated CpA dicnuleotides in brain from Mecp2-null mice 
[116]. Our tag enrichment analysis were more sensitive to binding changes in 
longer genes, simply because statistical power increases with tag count, and 
longer regions (gene bodies) have more changes of MeCP2 binding. Hence, our 
approach detected stronger binding differences in large genes. Thus binding of 
MeCP2 at mCG, mCH and hmC, along with the accompanying alteration in 
chromatin architecture can collectively play a role in regulating gene expression in 
mature neurons. 
Neuropathic pain models use nerve injury to induce hyperalgesia and 
allodynia in rodents. Neurons in the DRG are surrounded by an envelope of 
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satellite glial cells and it is now well established that immune and glial cell 
responses alter neuronal function in peripheral and central nervous system [125]. 
Our ChIP-seq study was performed using whole DRG and thus the findings 
reported here is from a mixed cell population. Comparison of cell specific global 
DNA methylation along with gene expression data will enable comparative study 
to confirm if methylation induced changes in MeCP2 binding resulted in gene 
expression changes. Plasticity of DNA methylation was recently investigated in rat 
DRG 24 hours after spinal nerve ligation, another peripheral nerve injury model of 
neuropathic pain. Though there was widespread remodeling of DNA methylation, 
comparison of genome-wide methylation and RNA-seq analysis of promoter 
regions and gene bodies showed that variation of methylation was not tightly linked 
with differences in gene expression [126]. The impact of DNA methylation on 
transcription is context dependent because methylation has been shown to either 
inhibit or promote gene expression, depending on the location of the mark [127]. 
MeCP2 is an abundantly expressed protein that seems to bind throughout the 
genome, and therefore it is plausible that in addition to regulating specific target 
genes, MeCP2 may broadly affect genome-wide transcription. 
MeCP2 alters gene expression through several mechanisms but MeCP2 
function itself is regulated, by miRNAs and several post translational modifications 
including activity dependent phosphorylation [128]. MeCP2 also suppress miRNA 
biogenesis by directly binding to DiGeorge syndrome critical region 8 (DGCR8), a 
critical component of the nuclear miRNA-processing machinery [129]. MeCP2-
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bound sequence tags indicated that miRNA regions were enriched for MeCP2 
binding in the SNI model compared to sham control. It has been proposed that the 
functions of miRNAs are more pronounced under stress or disease states [130], 
and alterations in MeCP2 binding could be one of the mechanisms contributing 
changes in miRNA expression. 
To investigate the impact of nerve injury induced redistribution, we studied 
miR-126, a miRNA with highest enrichment for MeCP2 binding post nerve injury. 
miR-126 is encoded within the intron of Egfl7 and highly expressed in brain [131]. 
A recent study demonstrated a role for miR-126 in reducing inflammation and 
improving the functional deficit after spinal cord injury. miR-126 decrease 
promoted angiogenesis and inflammation in the spinal cord after a weight induced 
contusion, and  administration of miR-126 reduced locomotor deficit and tissue 
damage [132]. Nerve injury induced upregulation of MeCP2 and a decrease in 
miR-126 after SNI. There was no MeCP2 binding at the miR-126 locus in sham 
control mice. Furthermore, Mecp2-null mice and their wild type littermates have 
similar levels of miR-126. This indicates that nerve injury induces the enriched 
binding of MeCP2 to miR-126 locus, resulting in miR-126 repression. We also 
observed increased expression of Vegfa and Dnmt1 in the SNI model. Dnmt1 and 
Vegfa are two validated target genes of miR-126 [118, 122]. Both genes are 
implicated to have a role in peripheral pain mechanisms. Dnmt1 is necessary for 
maintenance methylation, gene regulation, and chromatin stability [133]. Dnmt1 
mutations in humans contribute to hereditary sensory neuropathy [134], and 
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autonomic neuropathy [135]. Our current work and others have shown 
upregulation of Dnmt1 in the DRG after peripheral nerve injury [136].  Vegfa 
regulates angiogenesis in both development and various pathologies [137]. In the 
chronic constriction injury model of neuropathic pain, Vegfa and its receptor was 
upregulated in the DRG, and addition of anti-Vegf antibody increased thermal and 
mechanical withdrawal latency [119]. We observed increased Vegfa mRNA in the 
DRG after SNI. miR-126 regulation of these targets are further supported by our 
molecular studies. Mecp2-null mice had reduced levels of Dnmt1 and Vegfa. 
Reduced transcript levels in Mecp2-null mice can be interpreted as MeCP2 having 
a role in activation of these genes. Since we did not observe a significant binding 
of MeCP2 to Dnmt1 and Vegfa, one of the indirect mechanisms contributing to 
their upregulation after SNI could be the repression of miR-126 by MeCP2.  
DNA methylation is a very stable epigenetic modification. Since SNI and 
sham DRG had an identical methylation pattern at miR-126 locus, increased 
binding of MeCP2 to miR-126 can be considered to be independent of the 
methylation status, but dependent on nerve injury. Likely, nerve injury changes the 
chromatin architecture, allowing increased access for MeCP2 to bind miR-126 
locus. Further studies are needed to explore the role of MeCP2 in altering 
chromatin availability. 
Administration of miR-126 did not alter the pain threshold in mice after SNI, 
and this could be due to the severity of nerve injury used to generate chronic 
neuropathic pain. miRNAs are fine tuners of gene expression and the low pain 
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threshold generated by SNI could have been too severe for a single miRNA to 
reverse. Acting as a rheostat, the influence of miRNAs is often described as 
modest. As was reported for the studies in a spinal cord injury model [132], the 
role of miR-126 in reversing inflammation and functional deficits could not be 
captured in the behavioral assessments we employed. Future studies in less 
severe nerve injury or inflammatory pain models that may capture the involvement 
of Vegfa should be explored. Several miRNAs showed changes in MeCP2 binding 
after SNI. Administering a cocktail of these miRNAs, to regulate a larger number 
of downstream target genes, could potentially be beneficial in conferring analgesic 
effects. 
Collectively, these studies show that MeCP2 broadly binds chromatin, 
affecting numerous downstream targets. This study implicates a regulatory role for 
MeCP2, providing a molecular basis to better understand how epigenetic changes 
induce alterations in gene expression that occur in the DRG after nerve injury.  
 
 
 
 
 
100 
 
CHAPTER 3: Figure legends and Figures 
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Figure 1: Genome-wide MeCP2-DNA binding profile in DRG from SNI and sham 
control mice  
A-B, Genomic distribution of peaks from ChIP-seq in the sham and SNI samples. 
C, Enrichment of MeCP2 binding to genomic regions in the SNI and sham models. 
D, Common and unique broad peaks identified in regions encoding mRNAs in SNI 
and sham. ChIP-seq data was generated from 2 IP samples each for SNI and 
sham. Each sample contained L4, L5, and L6 ipsilateral DRG obtained from 10 
mice each, 4 weeks after surgery. 3UTR: 3’untranslated region, 5UTR: 
5’untranslated region, ncRNA: noncoding RNA, Pseudo: pseudo genes, rRNA: 
ribosomal RNA, TTS:  transcription termination sites. 
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Figure 2: Redistribution of MeCP2 binding in the DRG after nerve injury  
A, Genome-wide distribution of enriched peaks representing putative MeCP2 
binding sites that are at least 4 fold higher in the SNI model compared to sham 
control. B, Genomic redistribution of MeCP2 binding determined by enriched 
peaks in the SNI and sham model indicates increased MeCP2 binding to 
transcriptionally relevant regions and non-coding RNAs. 3UTR: 3’untranslated 
region, 5UTR: 5’untranslated region, ncRNA: noncoding RNA, Pseudo: pseudo 
genes, rRNA: ribosomal RNA, TTS:  transcription termination sites; NS: not 
significant, * p value < 1 x 10-3. 
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Figure 3: Enriched MeCP2 binding to miRNAs in the SNI model  
A, miRNA tag enrichment is greater in the SNI model compared to sham control, 
suggesting altered MeCP2-mediated regulation of miRNAs after nerve injury, p 
value 1.2 x 10-3 B, miRNAs listed have at least 4 fold tag enrichment in the SNI or 
sham model. miR-126 was the miRNA with the highest tag enrichment in the SNI 
model. 
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Figure 4: miR-126 locus has enriched MeCP2 binding in SNI model  
A, MeCP2 peak profile from ChIP-seq at miR-126a/miR-126b shows enrichment 
of MeCP2 binding to miR-126 locus in the SNI model, and virtually no binding in 
the sham control. B, Histogram showing fold change enrichment of MeCP2 binding 
to miR-126 in the SNI model. C, CpG methylation of miR-126 locus was identical 
in SNI and sham control mice. Bisulfite sequencing of the 72 bp sequence of 
premiR-126 locus harboring 6 CpG sites using DRG genomic DNA obtained from 
SNI and sham control mice showed methylation of all CpG sites in both SNI and 
sham samples (n=3). Identical methylation pattern in SNI and sham control 
indicates that SNI does not alter the methylation pattern of premiR-126 locus.  
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Figure 5: miR-126 regulates expression of Dnmt1 and Vegfa in vitro  
A, Relative expression of  endogenous Dnmt1 and Vegfa  mRNA in Neuro 2a cells 
transfected with miR-126  Gapdh was used as a normalizer. B, Representative 
western blot of Dnmt1 and Vegfa using lysate of Neuro 2a cells transfected with 
miR-126 precursor plasmid for 72 hours. Overexpression of miR-126 decreased 
mRNA and protein levels of Dnmt1 and Vegfa. β tubulin was used as the control. 
C, Immunohistochemistry indicating transfection with miR-126 plasmid co-
expressing GFP in Neuro 2a cells decreased Dnmt1 levels compared to 
untransfected cells 72 hours post transfection. Significance determined using 
Student’s t-test, p value *<0.05, ***<0.001 (n=3 for all samples). 
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Figure 6: Expression of miR-126 and its target genes Dnmt1 and Vegfa in the 
DRG after nerve injury  
A, Relative expression of miR-126 determined by qPCR shows a reduction in miR-
126 in SNI model compared to DRG from sham control. U6 was used for 
normalization (n=8 sham, n=7 SNI). B, Relative expression of Dnmt1 mRNA and 
C, Vegfa transcripts showed an increase in the DRG after nerve injury compared 
to control (n=3). Gapdh was used as a normalizer. D, Representative western blot 
and quantification showed an increase of Dnmt1 protein in the DRG after nerve 
injury. E, Western blot and quantification showed Vegfa protein was not 
significantly different in DRG after nerve injury (n=3 from pooled samples, 3 DRG 
were pooled for each sample). Significance determined using Student’s t-test, p 
value *<0.05. 
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Figure 7: Expression of miR-126 and its target genes Dnmt1 and Vegfa in the 
DRG from Mecp2-null mouse  
A, Relative expression of miR-126 in the DRG showed comparable expression in 
Mecp2-null and wild type littermates. U6 was used for normalization. B, Dnmt1 and 
C, Vegfa expression were decreased in the DRG from Mecp2-null mouse, 
indicating MeCP2 has a role in regulating expression of Dnmt1 and Vegfa. Gapdh 
was used as a normalizer. Significance determined using Student’s t-test, p value 
*<0.05, **<0.01 (n=3 for Mecp2-null (-/y) and wildtype littermate mice (+/y). 
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Figure 8: Administration of exogenous miR-126 decreased Dnmt1 and Vegfa 
expression in vivo but did not alter pain sensitivity  
A, Mechanical sensitivity measured by von Frey filaments indicated that intrathecal 
delivery of miR-126 did not alter the paw withdrawal threshold in SNI model mice. 
Arrows indicate daily intrathecal injections with 2nmol miR-126 or control miRNA 
via catheter (n=5 for miR-126 and miR-control injected mice, n=3 for PBS injected 
mice). B, Confirmation of miR-126 delivery to DRG. A qPCR performed using DRG 
collected from mice injected with miR-126 or control miRNA showed an increase 
in miR-126 in mice that received miR-126 compared to miR-control injected mice 
indicating successful delivery. C, Relative expression of Dnmt1 and Vegfa mRNA 
in the DRG of miR-126 and control injected mice. Increased miR-126 decreased 
the expression of endogenous Dnmt1 and Vegfa compared to control miRNA 
injected mice. Significance determined using Student’s t-test, p value, **<0.01, 
***<0.001. (n=5 for miR-126 and miR-control injected mice, n=3 for PBS injected 
mice). D, Schematic representation of nerve injury induced alterations of MeCP2 
binding and downstream gene expression changes. SNI induced enriched binding 
of MeCP2 to miR-126 locus resulting in repression of miR-126. Lower miR-126 
leads to increased expression of its two target genes Vegfa and Dnmt1. Vegfa 
could contribute to the progression of pain pathology by modulating angiogenesis 
and neuro-inflammation. Dnmt1 propagate established methylation patterns during 
cellular division by recognizing and copying parent strand methylation at 
symmetrical CG dinucleotides to the newly synthesized daughter strand and its 
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increase after SNI can alter or maintain methylation, and may contribute to gene 
expression changes ensuing SNI. 
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Table 1: Top ten MeCP2 enriched binding sites in the SNI model 
Top ten MeCP2 enriched promoters and genes identified by ChIP-seq in the DRG 
from the SNI model compared to sham control. 
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Table 1 
 
 
 
 
  
Nearest Refseq Gene Name Gene Description sham SNI p  value
NM_021478 Tulp1 tubby like protein 1 0 30 2.85E-06
NM_027398 Kcnip1 Kv channel-interacting protein 1 0 19 0.000195
NM_170757 Ccdc186 coiled-coil domain containing 186 0 16 0.000629
NM_001034898 Ms4a15 membrane-spanning 4-domains, subfamily A, member 15 0 25 1.92E-05
NR_033168 Snora28 small nucleolar RNA, H/ACA box 28 0 26 1.31E-05
NM_001113379 Lrrc32 leucine rich repeat containing 32 0 25 1.92E-05
NM_011305 Rxra retinoid X receptor alpha 0 15 0.000932
NM_018820 Sertad1 SERTA domain containing 1 0 17 0.000425
NM_001011525 Olfr1415 olfactory receptor 1415 0 16 0.000629
NM_133759 Zbtb3 zinc finger and BTB domain containing 3 0 25 1.92E-05
NM_001001807 Olfr279 olfactory receptor 279 0 21 8.97E-05
NM_011540 Tcap titin-cap 0 16 0.000629
NM_011971 Psmb3 proteasome (prosome, macropain) subunit, beta type 3 0 19 0.000195
NM_198414 Paqr9 progestin and adipoQ receptor family member IX 0 20 0.000132
NM_133668 Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 0 15 0.000932
NM_001160356 Uqcc3 ubiquinol-cytochrome c reductase complex assembly factor 3 0 15 0.000932
NM_001190356 Gm4832 predicted gene 4832 0 15 0.000932
NM_133759 Zbtb3 zinc finger and BTB domain containing 3 0 25 1.92E-05
NM_009296 Supt4a suppressor of Ty 4A 0 20 0.000132
NM_009756 Bmp10 bone morphogenetic protein 10 0 18 0.000288
Tag count
Gene bodies with enriched MeCP2 binding
Promoters with enriched MeCP2 binding
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CHAPTER FOUR: Summary and Future Directions 
  
125 
 
OVERALL SUMMARY 
This thesis was aimed at obtaining a fresh perspective and understanding of the 
molecular mechanisms underlying chronic pain mediated by epigenetic regulation. 
We investigated the mechanism and functional consequences resulting from 
upregulation of methyl-CpG-binding protein 2 (MeCP2) in the dorsal root ganglia 
(DRG), in mediating nerve injury induced chronic pain. 
 MeCP2 is critical for neuronal growth and function and dysregulation leads 
to neurological disorders, therefore, it is important to identify mechanisms of 
regulating MeCP2. Our previous study found 12 miRNAs predicted to target 
MeCP2 that were downregulated after nerve injury, and here, we further explored 
the regulation of MeCP2 by miRNAs. First, we demonstrate in vitro that miR-301 
and miR-19a bind to the 3’untranslated region (UTR) of MeCP2 and regulate 
expression through translational repression. Downregulation of these miRNAs in 
the DRG is linked with upregulation of MeCP2 after nerve injury.  We also showed 
that repression of MeCP2 by miRNAs affects MeCP2 mediated regulation of brain 
derived neurotrophic factor (Bdnf). MeCP2 has been shown to regulate Bdnf 
expression, and disruption of Bdnf is observed in Mecp2-null mice [31]. We found 
that Mecp2-null and MeCP2 T158A mice have decreased Bdnf in the DRG. 
MeCP2 T158A mice also have reduced sensitivity to an acute mechanical 
stimulus. Bdnf is an important modulator of sensory neurotransmission, with most 
of its biological effects mediated by the TrkB receptor. Signaling through this 
receptor contributes to the induction and maintenance of pain [106]. This could in 
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part explain why MeCP2 mutant mice and Rett syndrome (RTT) patients have 
decreased sensitivity. Together, these studies demonstrate that miRNA-mediated 
regulation of MeCP2 in the DRG and concomitant regulation of Bdnf could be 
important in pain sensation, and we demonstrate how a mutation in MeCP2 that 
leads to RTT causes reduced mechanical sensitivity. 
 The next set of studies presented here investigated the relationship 
between increased levels of MeCP2, and how this alters gene expression in the 
DRG after nerve injury. ChIP sequencing has been performed in the brain and 
subpopulations of neuronal and glial cells, however, this is the first MeCP2 ChIP-
seq study conducted in the DRG. Additionally, our genome-wide comparative 
analysis of the MeCP2 binding profile after nerve injury identified differentially 
bound regions of the genome. This study addresses the role of MeCP2 in pain, 
and furthermore, our investigation of miR-126 demonstrates how changes in 
MeCP2 binding after nerve injury can have direct and indirect effects on regulation 
of genes. 
 We predicted that upregulation of MeCP2 leads to increased MeCP2 bound 
chromatin. Surprisingly, we found that total binding sites were similar between the 
spared nerve injury (SNI) and sham samples. However, MeCP2 binding was 
redistributed from intergenic regions to transcriptionally relevant regions and non-
coding RNAs, and over 3,000 mRNAs were uniquely bound by MeCP2 in the SNI 
model. This data collectively suggests that a large number of genes are subjected 
to differential regulation by MeCP2. We additionally measured mRNA levels of 
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seven genes with enriched MeCP2 binding that are linked to pain, and found they 
were trending toward or were significantly upregulated in the SNI model (Figure 
1). It has been previously described that MeCP2 has a role in regulating 
transcriptional noise [28], and our observation of a broad alteration in gene 
expression suggests that nerve injury-induced redistribution of MeCP2 could have 
a role in modulating transcriptional noise that leads to changes in gene expression. 
Correlating our MeCP2 genome-wide binding data with transcriptional profiling of 
the DRG would help elucidate if the redistribution of MeCP2 leads to altered gene 
expression.  
We explored the functional outcomes of enriched MeCP2 binding to miRNA 
loci by investigating miR-126. MeCP2 was not bound to the miR-126 locus in sham 
mice, but was highly enriched after nerve injury. Our data indicate that enriched 
binding of MeCP2 represses miR-126 and results in increased expression of 
confirmed targets, DNA methyl transferase 1 (Dnmt1) and vascular endothelial 
growth factor (Vegfa). In order to determine the role of MeCP2 regulation of miR-
126 in a naïve state, we measured expression in the DRG from Mecp2-null mice 
and found no changes in miR-126 levels compared to wild type littermates. We 
concluded that MeCP2 does not play a role in regulation of miR-126 until binding 
is induced by nerve injury. 
The mechanism by which MeCP2 mediated regulation of miR-126 affects 
pain was evaluated by exploring validated targets of miR-126, Dnmt1 and Vegfa. 
Both genes are implicated to have a role in peripheral pain mechanisms. Dnmt1 is 
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necessary for maintenance methylation, gene regulation, and chromatin stability 
[133]. Mutations in DNMT1 in humans contribute to hereditary sensory neuropathy 
[134], and autonomic neuropathy [135]. Our current work and others has shown 
upregulation of Dnmt1 in the DRG after peripheral nerve injury [136].  Vegfa 
regulates angiogenesis in both development and various pathologies [137]. In the 
chronic constriction injury model of neuropathic pain, Vegfa and its receptor were 
upregulated in the DRG, and administration of anti-Vegf antibody increased 
thermal and mechanical withdrawal latency [138]. In this study, we observed 
increased Vegfa mRNA in the DRG after SNI, and confirm miR-126 regulation of 
Dnmt1 and Vegfa with both in vitro and in vivo overexpression studies.  
These experiments demonstrate that MeCP2 can indirectly regulate 
expression of Dnmt1 and Vegfa, through miR-126. To evaluate the direct 
regulatory role of MeCP2 on these targets, we measured transcripts in the DRG of 
Mecp2-null mice. Both Dnmt1 and Vegfa were significantly downregulated. We 
therefore conclude that activation of Dnmt1 and Vegfa is either directly or indirectly 
dependent upon MeCP2, while miR-126 is responsible for repression (Figure 2).  
We investigated the methylation changes occurring directly on the miR-126 
locus where MeCP2 binding was detected. Based on the enrichment of MeCP2 
after nerve injury, we also expected increased methylation, particularly since the 
miR-126 locus has a high incidence of CpG sites and therefore could be subjected 
to methylation changes [139]. We found that CpG sites had an identical 
methylation pattern in both SNI and sham DRG. Nerve injury likely changes 
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chromatin structure, allowing increased access for MeCP2 to bind miR-126. 
Further studies are required to explore how nerve injury alters nucleosome 
positioning and how redistribution of MeCP2 induces or responds to these 
alterations. 
Intrathecal injection of miR-126 confirmed the molecular mechanism in that, 
overexpression of miR-126 resulted in downregulation of Dnmt1 and Vegfa. 
However, exogenous miR-126 did not reverse mechanical allodynia or 
hyperalgesia associated with the SNI model. Likely, a single miRNA with targets 
that are involved in gene regulation and inflammation would not be therapeutic in 
this severe neuropathic pain model. It is also possible that this mechanism has 
temporal limitations; repressing Dnmt1 and Vegfa may be more efficacious at an 
earlier time point, or even prior to SNI surgery. Another group saw significant 
alteration of mechanical allodynia by administering miR-124 immediately after SNI 
surgery [50]. It may be difficult to reverse a behavioral phenotype by miRNA 
administration 4 weeks post-surgery, when molecular modifications have 
significantly progressed.  
Dnmt1 is responsible for methylation of hemimethylated CpG sites after cell 
division. Increased levels of Dnmt1 after nerve injury could have effects on the 
global methylation pattern in the DRG. This may be particularly evident in actively 
dividing cells, such as astrocytes and glia. The resulting methylation changes could 
directly repress gene expression, or could influence MeCP2 binding patterns. 
Therefore, it would be interesting to evaluate global methylation changes in 
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specific populations of cells in the DRG. Further studies determining how MeCP2 
binding correlates with changes in methylation pattern, and the global effects on 
transcriptional profile in the DRG should be pursued to explore this concept. 
This work demonstrates the role of MeCP2 in pain in a peripheral nerve 
injury model. Research on MeCP2 has mostly been focused on the central nervous 
system. Here, we demonstrate that MeCP2 can play a significant role in the 
peripheral nervous system. We initiated studies by assessing miRNA-mediated 
regulation of MeCP2, followed by a genome-wide ChIP-seq study and an in-depth 
analysis of miR-126 in the DRG. Our global study served to identify differentially 
bound genes after nerve injury, and both genome-wide and gene specific follow 
up studies will be beneficial to further elucidate the role of MePC2 in mediating 
pain. While our goal was to link MeCP2 to pain, this work is also relevant to the 
RTT community. RTT patients suffer from physical disabilities, reduced motor 
function, and altered pain sensitivity. This implicates a role for MeCP2 in the 
peripheral nervous system. Studies conducted in the periphery could contribute to 
the growing body of work investigating the many physical abnormalities associated 
with RTT. 
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FUTURE DIRECTIONS 
Further investigation of the role of MeCP2 in pain modulation is important in 
understanding how epigenetic regulators can affect gene expression related to 
pain sensation and processing. This study is the first step in evaluating how 
MeCP2 effects expression of genes in the DRG. 
 After conducting genome-wide comparative analysis of MeCP2 binding in 
the DRG, we found 14 miRNAs that were highly enriched for MeCP2 binding. In 
this study we focused on miR-126, however it would be interesting to expand the 
investigation to other miRNAs in this list, for example miR-487b and miR-877. miR-
487b is predicted to regulate expression of GRM3, a metabotropic glutamate 
receptor with a role in pain, and miR-877 is predicted to regulate β-tubulin [41], 
which could result in polymerization changes associated with neuropathic pain. 
Increased binding of MeCP2 could lead to differential expression of these 
regulatory miRNAs and may contribute to the progression of chronic pain through 
regulation of their predicted targets. Further studies including confirmation of target 
binding, repression of target expression, and in vivo administration followed by 
behavioral assessment could be pursued. There are also 21 miRNAs that have 
reduced MeCP2 binding in the SNI model compared to sham. This could lead to 
altered miRNA levels after nerve injury and ultimately affect target expression. 
miR-27a  has reduced MeCP2 binding in the SNI model and regulates transcription 
factors RUNX1 [140] and FOXO1 [141]. RUNX1 is expressed in non peptidergic 
nociceptors and regulates expression of several ion channels and mu opioid 
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receptors [142].These transcription factors affect a large number of downstream 
genes and further investigation of their targets could provide a mechanistic link to 
pain. 
miRNAs are fine tuners of gene expression and individually can have 
relatively small effects. It would be interesting to investigate changes in pain 
sensitivity after administration of a cocktail of miRNAs instead of individual 
miRNAs. Each miRNA has multiple targets, therefore administration of several 
miRNAs would have diverse molecular effects and could broaden the therapeutic 
potential. One issue with this approach is that regulation of multiple molecular 
targets could heighten the potential for side effects. This would have to be 
evaluated on an individual miRNA basis. Advances in miRNA administration to 
specific target cells and tissue will be critical in increasing the therapeutic potential 
of miRNAs. 
 To better understand regulation of miRNAs, studies can be conducted to 
identify methylation pattern and enrichment of MeCP2 binding within the promoter 
of miRNAs and genes. Promoter regions have not been mapped for most miRNAs; 
there are often multiple transcriptional start sites [12], and promoters can be 
intronic, exonic, or shared with the promoter of the host gene [13]. The promoter 
for miR-126 has not been defined, however, it could be shared with one of the 
promoters of its harboring gene, Egfl7, as expression of the gene and miRNA seem 
to be proportional [139]. This T2 promoter also contains a CpG island, and 
typically, methylation at promoters is associated with gene silencing. Evaluating 
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the methylation status of this putative promoter may help us further understand 
how nerve injury and enriched MeCP2 binding repress miR-126 expression in the 
DRG. 
 There are many loci enriched for MeCP2 after SNI surgery. We measured 
expression levels of selected genes with potential roles in pain (Figure 1). Of the 
seven genes we measured, all were upregulated in the DRG after nerve injury. 
Further evaluation of the direct or indirect role of MeCP2 in regulation of these 
individual genes and their contribution to pain is necessary to better understand 
the role of MeCP2 in pain in the peripheral nervous system. Our comparative 
analysis focused on genes with enriched binding in the SNI model compared to 
sham. However, the reciprocal approach should also be taken to investigate genes 
with less MeCP2 binding in SNI compared to sham. This would reveal a new list 
of differentially bound genes that could have a role in mediating pain. 
 Finally, we found that MeCP2 levels are decreased in the dorsal horn of the 
spinal cord after nerve injury and we conducted ChIP-seq on these samples. While 
this work is not included in the thesis presented here, we will conduct a 
comparative analysis and evaluate genes with enriched binding and altered 
expression in the SNI model. This study will further elucidate how an epigenetic 
regulator can influence gene expression relevant to pain. 
 
  
134 
 
CHAPTER: Figure Legends and Figures 
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Figure 1: Expression of genes with enriched MeCP2 binding in the SNI model 
qPCR was used to determine transcript levels of genes that had comparatively 
enriched MeCP2 binding in the SNI model versus sham model. These genes were 
selected from a larger list as having potential roles in pain. Significance determined 
by Student’s t-test, p value *<0.05 
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Figure 1 
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Figure 2: Schematic representation of Dnmt1 and Vegfa regulation 
We propose that Dnmt1 and Vegfa is dependent upon MeCP2 for activation and 
miR-126 for repression. This homeostasis is disrupted in the SNI model. MeCP2 
repression of miR-126 leads to upregulation of these targets. 
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